



# ***Athlete Biological Passport Operating Guidelines***

**Version 8.0**

April 2021

## Table of Contents

Content.....	3
<b>Part One: Introduction and Objectives.....</b>	<b>4</b>
1.1 Introduction to the <i>Athlete Biological Passport</i> .....	4
1.2 Objectives .....	4
<b>Part Two: Modules, Management and Administration .....</b>	<b>5</b>
<b>2.1 Modules.....</b>	<b>5</b>
2.1.1 Haematological Module .....	5
2.1.2 Steroidal Module .....	6
<b>2.2 Resources, Partner Roles and Responsibilities.....</b>	<b>6</b>
2.2.1 Resources.....	6
2.2.2 Specific Partner Responsibilities .....	7
2.2.2.1 <i>Anti-Doping Organization (ADO)</i> .....	7
2.2.2.2 <u>Athlete Passport Management Unit (APMU)</u> .....	7
2.2.2.3 <u>Laboratory</u> .....	8
2.2.2.4 <u>Experts</u> .....	8
<b>2.3 ABP Management and Administration .....</b>	<b>9</b>
2.3.1 <i>Testing</i> and Defining the Target <i>Athletes</i> .....	9
2.3.2 <i>Athlete</i> Information.....	9
2.3.3 Standardization through <i>ADAMS</i> .....	10
2.3.4 <u>APMU Report</u> .....	10
2.3.5 Recommended Administrative Sequence.....	11
2.3.6 <i>ABP</i> Administrative Sequence Graphic .....	11
2.3.7 Role of the <u>Passport Custodian</u> .....	13
2.3.8 Attribution and Transfer of <u>Passport Custody</u> .....	13
<b>Part Three: Mandatory Protocols.....</b>	<b>14</b>
3.0 Scope .....	14
3.1 Collection, Storage and Transport of Blood <i>Athlete Biological Passport Samples</i> (ISTI Annex I) .....	15
3.2 Analytical Requirements for the Hematological Module of the <i>Athlete Biological Passport</i> .....	19
3.3 Measurement and Reporting of Endogenous Anabolic Androgenic Steroids (EAAS) Markers of the Urinary Steroid Profile .....	25
3.4 <i>Results Management</i> Requirements and Procedures for the <i>Athlete Biological Passport</i> (ISRM Annex C) .....	35
3.5 <u>Athlete Passport Management Unit</u> Requirements and Procedures.....	45
<b>Part Four: Collaboration Agreement Template .....</b>	<b>61</b>

## Content

This document is divided into four parts.

**Part One** provides background and context for the creation of the *Athlete Biological Passport (ABP)*, introduces the Haematological and Steroidal Modules of the Passport and explains the role of the *ABP* Operating Guidelines in supporting *Anti-Doping Organizations (ADOs)*.

**Part Two** describes the Modules and explains the principles for the implementation of the *ABP* by an *ADO*.

**Part Three** contains Annexes of the *International Standard for Results Management (ISRM)*, the *International Standard for Testing and Investigations (ISTI)* in connection with *Technical Documents* that specify mandatory protocols to be followed by *ADOs*, *Laboratories*, and *Athlete Passport Management Units (APMUs)* in order to run an *ABP* program.

**Part Four** includes a template agreement developed by *WADA* for the sharing of Passport information between multiple *ADOs* (supported by *ADAMS*).

[For the purpose of these Guidelines, *Code* definitions are in *Italics*. *International Standard* definitions are Underlined.]

---

# Part One: Introduction and Objectives

## 1.1 Introduction to the *Athlete Biological Passport*

The term “athlete biological passport” was first proposed in the early 2000s by the scientific community when monitoring of select haematological variables (*Markers* of blood doping) was identified as a means to define an individual’s haematological profile. In conjunction with several stakeholders and medical experts, the World Anti-Doping Agency (*WADA*) began to further develop, harmonize and validate this concept. The result was a formal operating guideline and mandatory standards known as the *Athlete Biological Passport (ABP)*, first published in 2009, which concerned exclusively the Haematological Module.

In 2014, the initial system was complemented with the Steroidal Module, which was launched in order to establish longitudinal profiles of an *Athlete’s* steroid variables.

The framework proposed in these Guidelines builds on existing anti-doping infrastructure to promote harmonization in *ABP* Programs, facilitate exchange of information and mutual recognition of data and, consequently, to enhance efficiencies in the operation of Anti-Doping Activities.

These Guidelines provide a harmonized process for both the Haematological Module and the Steroidal Module of the *ABP*, following nearly identical administrative procedures in *ADAMS*.

As with all Guidelines, this document is subject to ongoing review and assessment to ensure it continues to reflect best practice moving forward. *WADA* encourages feedback on this document and recommends stakeholders to consult *WADA’s* Web site, <http://www.wada-ama.org> for the latest version.

## 1.2 Objectives

The principal objectives of integrating the *ABP* into the larger framework of a robust anti-doping program are the following:

1. The *ABP* can be used to identify *Athletes* requiring further attention through intelligent, timely interpretation of Passport data. The *ABP* provides valuable information that can be used to direct *Target Testing* or investigations more effectively. The *ABP* can notably be used as a complement to analytical methods to further refine and strengthen overall anti-doping strategies:
  - i) For the Haematological Module, this could be, for example, *Testing* for Erythropoiesis-Stimulating Agents<sup>1</sup> (ESAs) or homologous blood transfusion (HBT).
  - ii) For the Steroidal Module, this could be, for example, the use of Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS) to

---

<sup>1</sup>Described in Section S2.1 of the *Prohibited List* as erythropoietins (EPO) and agents affecting erythropoiesis.

detect endogenous steroids administered exogenously.

2. A Passport may be used to pursue an Anti-Doping Rule Violation (ADRV) in accordance with World Anti-Doping Code (*Code*) Article 2.2. Through changes in biological *Markers* of doping collated over an *Athlete's* career, the *ABP* can be used to establish 'Use' per *Code* Article 2.2 without necessarily relying on the detection of a particular *Prohibited Substance* or *Prohibited Method*. This approach has proven effective in establishing ADRVs without having to rely on traditional analytical approaches.

## Part Two: Modules, Management and Administration

### 2.1 Modules

#### 2.1.1 Haematological Module

The Haematological Module collects information on *Markers* of blood doping. This Module aims to identify the *Use of Prohibited Substances* and/or *Prohibited Methods* for the enhancement of oxygen transport or delivery, including the *Use of ESAs* and any form of blood transfusion or manipulation.

In addition to identifying the use of ESAs included under section S2 of the *Prohibited List* (Peptide Hormones, Growth Factors, Related Substances and Mimetics), the Haematological Module also seeks to identify the *Use of Prohibited Methods* categorized under section M1 of the *Prohibited List* (Manipulation of Blood and Blood Components).

The following blood variables are considered within the *ABP* Haematological Module:

- ABPS: Abnormal Blood Profile Score
- HCT: Haematocrit
- HGB: Haemoglobin
- IRF: Immature reticulocyte fraction
- MCH: Mean corpuscular haemoglobin
- MCHC: Mean corpuscular haemoglobin concentration
- MCV: Mean corpuscular volume
- OFFS: OFF-hr Score
- PLT: Platelets
- RBC: Red blood cell (erythrocyte) count
- RDW-SD: Red cell distribution width (standard deviation)
- RET#: Reticulocyte count
- RET%: Reticulocytes percentage
- WBC: White Blood Cells

## 2.1.2 Steroidal Module

The Steroidal Module collects information on *Markers* of steroid doping. The Module aims to identify endogenous anabolic androgenic steroids (EAAS) when administered exogenously and other anabolic agents, such as selective androgen receptor modulators (SARMS) categorized under Section S1.2 of the *Prohibited List*. The Steroidal Module is also an effective means to identify *Samples* which may have been tampered with or exchanged with the urine of another individual (*Code Article 2.5*).

The following *Markers* are considered within the *ABP* Steroidal Module, as detailed in the *Technical Document* on Measurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) Markers of the Urinary Steroid Profile (TD EAAS, see Section 3.3 below):

- A: Androsterone
- Etio: Etiocholanolone (Etio)
- 5 $\alpha$ Adiol: 5 $\alpha$ -Androstane-3 $\alpha$ ,17 $\beta$ -diol
- 5 $\beta$ Adiol : 5 $\beta$ -Androstane-3 $\alpha$ ,17 $\beta$ -diol
- T: Testosterone
- E: Epitestosterone

In addition to the following ratios:

- T/E
- A/T
- A/Etio
- 5 $\alpha$ Adiol/5 $\beta$ Adiol
- 5 $\alpha$ Adiol/E

## 2.2 Resources, Partner Roles and Responsibilities

The roles and responsibilities of the various partners implementing the *ABP* include test planning, conducting the *Sample* collection, profile interpretation and *Results Management*.

### 2.2.1 Resources

The following resources are required to adopt and implement the *ABP*:

- Access to a network of Doping Control Officers (DCOs) and Blood Collection Officers (BCOs) where necessary, operating in locations where target *Athletes* will be present.
- An effective whereabouts management system to facilitate *Athlete* location (i.e. *ADAMS*).
- Access to *ADAMS*, to administer the *ABP* Program.

- A WADA-approved Athlete Passport Management Unit (APMU) for the management of specific *ABP* processes.
- An Expert panel managed by the APMU qualified for the review of Passports.

[Comment: Access to the *ADAMS Biological Passport Guide* is available at the following link: <http://adams-docs.wada-ama.org/display/EN/ADAMS+Biological+Passport+guide>]

## 2.2.2 Specific Partner Responsibilities

### 2.2.2.1 Anti-Doping Organization (ADO)

The *ADO* is responsible for:

- Adopting, implementing and administrating an *ABP* program in accordance with these Guidelines, including compliance with applicable *International Standards* and *Technical Documents*.
- Contracting a WADA-approved APMU to manage the *ABP* program.

[Comment: The list of WADA-approved APMUs is available at the following link: <https://www.wada-ama.org/en/resources/athlete-biological-passport/list-of-athlete-passport-management-units-apmu>]

- Ensuring that recommendations received from the APMU are followed by effective, targeted, timely and appropriate *Testing*.
- Establishing, and implementing a test distribution plan, in consultation with the APMU.
- Sharing of relevant information with internal investigations personnel and other *ADOs* (when appropriate).
- Managing Passport custody and ensuring efficient Passport sharing with other *ADOs* having shared *Testing* jurisdiction over the *Athlete*.
- When the *ADO* is the Passport Custodian, following up on *Adverse Passport Findings (APFs)* in accordance with *Code* and *ISRM* requirements.
- When necessary, informing the *Athlete* in case the Passport indicates a likely pathology as determined by the Experts.

### 2.2.2.2 Athlete Passport Management Unit (APMU)

The APMU is responsible for:

- Timely management of the Passports in *ADAMS* on behalf of the Passport Custodian.
- Performing Passport assessments to make timely *Target Testing* recommendations to the *Anti-Doping Organization (ADO)* via the APMU Report in *ADAMS* when appropriate.
- Managing the review of atypical Passports according to Annex C of the *International Standard for Results Management (ISRM)* (Section 3.4 below), including, but not limited to, the following:

- Issuing and updating APMU Reports in *ADAMS*,
- In case of an *Atypical Passport Finding (ATPF)*, or when a review is otherwise justified, assigning and liaising with the Expert panel as required,
- Compiling all necessary information to establish an Athlete Biological Passport Documentation Package, and
- Declaring *Adverse Passport Findings (APFs)* to the Passport Custodian and *WADA*.
- Assessing and managing Passport Sample validity in *ADAMS*, in consultation with the Experts or Laboratories when necessary.
- Providing support to the Passport Custodian in defining priorities in order to optimize the efficiency of their *ABP* program. These priorities may include, but are not limited to, cost efficiency, special analyses, Test Distribution Plans, and *Target Testing*.

### 2.2.2.3 Laboratory

The Laboratory or ABP Laboratory is responsible for:

- Blood analysis: perform blood analysis in compliance with the *Technical Document on Analytical Requirements for the Hemtological Module of the Athlete Biological Passport* (Section 3.2 below).
- Urine analysis: perform urine analysis in compliance with the *Technical Document on Measurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) Markers of the Urinary Steroid Profile* (Section 3.3 below) for the measurement and reporting of urinary steroid profiles.
- Issuing a Certificate of Analysis or Laboratory Documentation Package as applicable.
- Providing additional information for interpretation of results and for complementary analysis.


### 2.2.2.4 Experts

The Experts are responsible for:

- Reviewing Passport data and results from the Adaptive Model in *ADAMS* provided by the APMU. The review shall identify any possible pathological or confounding conditions that may have impacted an *Athlete's* analytical results.
- Recommending follow-up *Testing* and/or suggesting possible clinical testing that may be required to a) confirm the assessment or b) collect further evidence to support or confirm possible pathologies.
- Reviewing any explanations given by the *Athlete* and providing an opinion on whether the Passport was likely the result of the Use of a Prohibited Substance or Prohibited Method.
- Working with the relevant APMU as required, and providing support as necessary throughout the *Results Management* and hearing process.

## 2.3 ABP Management and Administration

An *ABP* program is administered and managed by an APMU on behalf of the *ADO*. The APMU is the link between the Passport Custodian, the Laboratories, and the Expert panel. Within each Passport in *ADAMS*, the APMU Report provides a record of these various interactions for efficient follow-up by the Passport Custodian, *WADA* and other *ADOs* with whom the Passport is shared through *ADAMS*.



### 2.3.1 Testing and Defining the Target Athletes

An *ABP Testing* Program must follow the *ISTI*, *ISRM*, the *Technical Document* for Sport Specific Analysis (TD SAA) and applicable *Technical Documents* specific to the *ABP* (Part Three below).

Without limitation, the criteria listed in *ISTI* Article 4.2 are the factors that may be considered in determining the target population for the *ABP* in the context of an *ADO's* overall Test Distribution Plan (TDP).

Targeted tests that follow the recommendations of the APMU should be privileged over Random Selection Testing to improve the effectiveness of the *ABP*. In general, the effectiveness of the *ABP* to detect doping is improved where both *In-* and *Out-of Competition Testing* and No Advance Notice Testing are distributed strategically throughout the year.

*[Comment: For the Haematological Module, it is recommended to use data from samples collected 5 days apart or more to optimize the statistical significance of the data. This does not preclude Testing an Athlete less than five (5) days apart, notably and without limitation, when a potential risk of doping practices has been identified. The validity of the Samples and their inclusion in the Expert review is in any event not put in question by the collection frequency.]*

*When an ABP blood Sample is collected, the ADO must consider whether the collection of concomitant urine or blood Samples is warranted, under the circumstances, to perform traditional analysis. For Out-of-Competition Testing, it is recommended to collect urine Samples together with the blood Sample(s) in order to permit Analytical Testing for ESAs when required.]*

### 2.3.2 Athlete Information

Given that additional information is required from *Athletes* beyond what is collected in traditional *Doping Control* documentation pursuant to the *ISTI*, supplemental or revised documentation may be required. Such documentation may be collected as appropriate, both prior to and after *Testing*, for APMU assessment and Experts' review as required.

For *ABP* blood *Samples*, in addition to the mandatory information set out in ISTI Article 7.4.5, which must be recorded as a part of all Sample Collection Sessions, the information listed in ISTI I.2.9 (Section 3.1 below) shall be recorded in a specific *ABP* Supplementary Form or a related form to be signed by the *Athlete*.

[Comment: See the available *ABP* Supplementary Form template: <https://www.wada-ama.org/en/resources/world-anti-doping-program/athlete-biological-passport-supplementary-report-form>]

### 2.3.3 Standardization through *ADAMS*

The *ABP* Program is administered through *WADA's Anti-Doping Administration and Management System (ADAMS)*, a secure online database management tool for data entry, storage, sharing, and reporting, designed to assist stakeholders and *WADA* in their anti-doping operations. An essential element of the *ABP*, the Adaptive Model, is fully integrated into *ADAMS*. Only programs that fully utilize *ADAMS* can be considered *ABP* Programs.

Standardization and harmonization of *ABP* programs is achieved through the use of *ADAMS*. This ensures that all mandatory requirements are met and that the *Athlete Passports* are shared and stored securely, all in accordance with the *International Standard for the Protection of Privacy and Personal Information (ISPPPI)*. Furthermore, *ADAMS* facilitates prompt exchange of information between *ADOs*, APMUs, Laboratories and/or ABP Laboratory, Sample Collection Personnel, and *WADA*.

### 2.3.4 APMU Report

The APMU Report is a central element in the administrative sequence of the *ABP* that shall be entered and maintained by the APMU in *ADAMS*. The APMU Report provides an up-to-date overview of the current status of an *Athlete's Passport* together with recommendations, as appropriate, for efficient follow-up by the Passport Custodian. The APMU Report serves to update the Passport Custodian, *WADA* and other *ADOs* with whom the Passport is shared. In addition, it provides a record of events associated with a Passport in *ADAMS*.

The APMU Report may include, without limitations:


- Assessments of *Sample* validity by the APMU and/or Experts;
- Recommendations for complementary Analytical Testing (e.g., ESAs, HIF stabilizers, confirmation of steroid profile, GC/C/IRMS, long-term steroid *Metabolites*, IGF-I, etc.) on *Samples* collected;
- Recommendations for further Analytical Testing on *Samples* collected previously;
- Recommendations for storing of *Samples* for extended periods of time for Further Analysis;
- *Target Testing* recommendations based on available data and Experts' recommendations; and a summary of any recent Expert reviews.

### 2.3.5 Recommended Administrative Sequence


The following outlines the suggested sequence of interactions between the *Athlete*, Sample Collection Personnel, *ADOs*, Laboratory(ies), *ADAMS*, APMUs, and Expert panels to establish, follow up and review an individual *Athlete's* Passport in an effective and efficient manner.

The recommended administrative sequence outlined below may be modified or adapted to merge with existing anti-doping infrastructure, procedures and mechanisms as required. However these Guidelines aim to ensure that *ADOs* establish a process that demonstrates transparency in the planning, interpretation and *Results Management* aspects of an *ABP* program.

### 2.3.6 ABP Administrative Sequence Graphic



## ABP Administrative Sequence Graphic, cont.



## 2.4 Passport Custody and Sharing

For any individual *Athlete*, only one Passport should be established. Using *ADAMS* for the management of Passport information, *ADOs* enhance efficiency and program effectiveness through exchange of information and mutual recognition of program outcomes. Such coordination and reciprocal agreement reduce unnecessary duplication in resource expenditure and foster enhanced confidence among *ADOs* and *Athletes* alike.

All *Doping Control* biological results obtained for an *Athlete* are collated in his Passport regardless of the Testing Authority. Only a complete *Athlete's* Passport allows the correct determination of *Atypical Passport Findings* in *ADAMS*. Passport administration and possible *Results Management* can then follow in compliance with the *Code* with the assurance that the Passports are complete. *ADOs* that fail to share Passport data via *ADAMS* do not operate an *ABP* program.

Within the framework provided by the *ISPPPI*, *ADOs* are encouraged to coordinate their activities where multiple *ADOs* have *Testing* jurisdiction over a single *Athlete* and multiple *ADOs* may wish to perform Passport *Testing*. In the interests of a “one *Athlete* – one Passport” principle, *ADOs*

should work cooperatively to see that *Testing* is coordinated appropriately with all results collated in the *Athlete's Passport* in ADAMS.

### 2.4.1 Role of the Passport Custodian

Any individual *Athlete* has a Passport Custodian that ensures that all ADOs that have *Testing* jurisdiction over the *Athlete* do not work in isolation. The Passport Custodian is responsible for sharing Passport information with other ADOs to ensure proper coordination and best use of resource expenditure. WADA has developed a template agreement for the sharing of Passport information between multiple ADOs (supported by ADAMS), which is included herein in Part Four.

In the case of an ATPF, or when a review is otherwise justified, the Passport Custodian is responsible for initiating the Passport review process via its APMU and, if an APF is declared, for *Results Management* of the Passport in compliance with Annex C of the ISRM (Section 3.4 below), regardless of whether another ADO was the Testing Authority of the test that triggered the ATPF.

As outlined in ISTI Article 10.4, where the Testing Authority is not the Passport Custodian, the Testing Authority that initiated and directed the *Sample* collection maintains the responsibility for additional Analytical Testing of the *Sample*, including the performance of further Confirmation Procedure(s) upon requests generated automatically by the Adaptive Model of the ABP in ADAMS (e.g. GC/C/IRMS triggered by elevated T/E) or as requested by the APMU (e.g. GC/C/IRMS requested due to abnormal secondary *Markers* of the urinary “longitudinal steroid profile”; ESA tests due to suspicious haematological *Marker* values).

### 2.4.2 Attribution and Transfer of Passport Custody

In ADAMS, Passport custody is attributed to the Testing Authority that first tests the *Athlete*, independently of whether it is an ABP blood test, a urine test, or both. This process ensures that the custody will most likely automatically be assigned to the organization that has a real interest in the *Athlete*. When the *Athlete* is first tested by a *Major Event Organization (MEO)*, Passport custody is attributed to the IF. When a NADO first tests an *Athlete* with a different sport nationality, Passport custody is attributed to the IF. This can later be reassigned to the NADO of the sport nationality of the *Athlete* if appropriate.

Passport custody can be transferred in ADAMS by the Passport Custodian to another ADO with *Testing* jurisdiction over the *Athlete*. ADOs should have a procedure in place to monitor their pool of Passports at regular intervals (ex. quarterly) using the reporting functionalities in ADAMS in order to identify Passports potentially more suitable for management by another ADO. Reasons for transferring Passport custody may include a change in *Athlete* level, more frequent *Testing* by another ADO, or be based on a strategic agreement between ADOs with *Testing* jurisdiction over the *Athlete*. The Passport Custodian should make requests in writing regarding any transfers of Passport custody to the recipient ADO. If no agreement can be found on the Passport custody, WADA shall determine which ADO is the *Athlete's Passport Custodian*. WADA shall not rule on this without consulting the ADOs involved.

---

## Part Three: Mandatory Protocols

### 3.0 Scope

*ADOs* implementing an *ABP* Program shall follow mandatory protocols documented in Annexes of the *International Standard for Results Management* (ISRM) and *International Standard for Testing and Investigations* (ISTI). Included herein for the ease of reference, these requirements have been established to harmonize the results of monitored biological *Markers* within the *ABP* to ensure both legal fortitude and scientific certainty. This standardization of procedure allows for the sharing and mutual recognition of Passport data between the anti-doping programs of multiple *ADOs*. Only programs that fully adhere to these protocols and fully utilize *ADAMS* can be considered *ABP* Programs. These protocols are linked to *Technical Documents* that a Laboratory or ABP Laboratory shall follow for the analysis of *Samples* collected within the framework of the *ABP* (included herein for the sake of completeness).

Section 3.1 sets out the minimum requirements for *Sample* collection and *Sample* transport that an *ADO* shall fulfil to run the Haematological Module of the *ABP* program (Annex I of the ISTI). Sections 3.2 and 3.3 are *Technical Documents* intended for Laboratory or ABP Laboratory personnel that aim to harmonize the analysis of blood or urine *Samples* collected for the measurement of the *Markers* of the Haematological and Steroidal Modules of the *ABP*. Section 3.4 sets out the requirements and procedures that the Passport Custodian and its APMU shall follow for Result Management for the *ABP* (Annex C of the ISRM). Finally, Section 3.5 outlines the requirements and procedures for WADA-approved APMUs.

### 3.1 Collection, Storage and Transport of Blood *Athlete Biological Passport* Samples (ISTI Annex I)

#### I.1. Objective

To collect an *Athlete's* blood *Sample*, intended for use in connection with the measurement of individual *Athlete* blood variables within the framework of the *Athlete Biological Passport* program, in a manner appropriate for such use.

#### I.2. Requirements

**I.2.1** Planning shall consider the *Athlete's* whereabouts information to ensure *Sample* collection does not occur within two (2) hours of the *Athlete's* training, participation in *Competition* or other similar physical activity. If the *Athlete* has trained or competed less than two (2) hours before the time the *Athlete* has been notified of their selection, the DCO or other designated Sample Collection Personnel shall chaperone the *Athlete* until this two-hour period has elapsed.

**I.2.2** If the *Sample* was collected within two (2) hours of training or *Competition*, the nature, duration and intensity of the exertion shall be recorded by the DCO to make this information available to the APMU and subsequently to the Experts.

**I.2.3** Although a single blood *Sample* is sufficient within the framework of the *Athlete Biological Passport*, it is recommended to collect an additional B *Sample* for a possible subsequent analysis of *Prohibited Substances* and *Prohibited Methods* in whole blood (e.g., detection of Homologous Blood Transfusion (HBT) and/or Erythropoiesis Stimulating Agents (ESAs)).

**I.2.4** For *Out-of-Competition Testing*, A and B urine *Samples* should be collected together with the blood *Sample(s)* in order to permit Analytical Testing for ESAs unless otherwise justified by a specific intelligent *Testing* strategy.

*[Comment to I.2.4: WADA's Sample Collection Guidelines reflect these protocols and include practical information on the integration of Athlete Biological Passport Testing into "traditional" Testing activities. A table has been included within the Sample Collection Guidelines that identifies which particular timelines for delivery are appropriate when combining particular Test types (i.e., Athlete Biological Passport and Growth Hormone (GH), Athlete Biological Passport and Homologous Blood Transfusion, etc.), and which types of Samples may be suited for simultaneous transport.]*

**I.2.5** The *Sample* shall be refrigerated from its collection until its analysis with the exception of when the *Sample* is analyzed at the collection site without delay. The storage procedure is the DCO's responsibility.

**I.2.6** The storage and transport device shall be capable of maintaining blood *Samples* at a cool temperature during storage. Whole blood *Samples* shall not be allowed to freeze at any time. In choosing the storage and transport device, the DCO shall take into account the time of storage, the number of *Samples* to be stored in the device and the prevailing environmental conditions (hot or cold temperatures). The storage

device shall be one of the following:

- a) Refrigerator;
- b) Insulated cool box;
- c) Isotherm bag; or
- d) Any other device that possesses the capabilities mentioned above.

**I.2.7** A temperature data logger shall be used to record the temperature from the collection to the analysis of the *Sample* except when the *Sample* is analyzed at the collection site without delay. The temperature data logger shall be able to:

- a) Record the temperature in degrees Celsius at least once per minute;
- b) Record time in GMT;
- c) Report the temperature profile over time in text format with one line per measurement following the format “YYYY-MM-DD HH:MM T”; and
- d) Have a unique ID of at least six characters.

**I.2.8** Following notification to the *Athlete* that he/she has been selected for *Sample* collection and following the DCO/BCO's explanation of the *Athlete*'s rights and responsibilities in the *Sample* collection process, the DCO/BCO shall ask the *Athlete* to remain still, in a normal seated position, with feet on the floor for at least ten (10) minutes prior to providing a blood *Sample*.

*[Comment to I.2.8: The Athlete shall not stand up at any time during the ten (10) minutes prior to Sample collection. To have the Athlete seated during ten (10) minutes in a waiting room and then to call the Athlete into a blood collection room is not acceptable.]*

**I.2.9** The DCO/BCO shall collect and record the following additional information on an *Athlete Biological Passport* supplementary form, *Athlete Biological Passport* specific *Doping Control* form or other related report form to be signed by the *Athlete* and the DCO/BCO:

- a) Has the *Athlete* been seated for at least ten (10) minutes with their feet on the floor prior to blood collection?
- b) Was the *Sample* collected immediately following at least three (3) consecutive days of an intensive endurance *Competition*, such as a stage race in cycling?
- c) Has the *Athlete* had a training session or *Competition* in the two (2) hours prior to the blood collection?
- d) Did the *Athlete* train, compete or reside at an altitude greater than 1,500 meters within the prior two (2) weeks? If so, or if in doubt, the name and location of the place where the *Athlete* had been and the duration of their stay shall be recorded. The estimated altitude shall be entered, if known.

- e) Did the *Athlete* use any form of altitude simulation such as a hypoxic tent, mask, etc. during the prior two (2) weeks? If so, as much information as possible on the type of device and the manner in which it was used (e.g., frequency, duration, intensity) should be recorded.
- f) Did the *Athlete* receive any blood transfusion(s) during the prior three (3) months? Was there any blood loss due to accident, pathology or donation in the prior three (3) months? If so, the estimated volume should be recorded.
- g) Has the *Athlete* been exposed to any extreme environmental conditions during the last two (2) hours prior to blood collection, including any sessions in any artificial heat environment, such as a sauna? If so, the details should be recorded.

**I.2.10** The DCO/BCO shall start the temperature data logger and place it in the storage device. It is important to start recording the temperature before *Sample* collection.

**I.2.11** The storage device shall be located in the Doping Control Station and shall be kept secure.

**I.2.12** The DCO/BCO instructs the *Athlete* to select the Sample Collection Equipment in accordance with Annex D.4.6. If the collection tube(s) are not pre-labelled, the DCO/BCO shall label them with a unique *Sample* code number prior to the blood being drawn and the *Athlete* shall check that the code numbers match.

### **I.3. The *Sample* Collection Procedure**

**I.3.1** The *Sample* collection procedure for the collection of blood for the purposes of the *Athlete Biological Passport* is consistent with the procedure set out in Annex D.4., including the ten (10) minute (or more) seated period, with the following additional elements:

- a) The BCO ensures that the collection tubes were filled appropriately; and
- b) After the blood flow into the tube ceases, the BCO removes the tube from the holder and homogenizes the blood in the tube manually by inverting the tube gently at least three (3) times.

**I.3.2** The *Athlete* and the DCO/BCO sign the *Doping Control* and *Athlete Biological Passport* supplementary form(s), when applicable.

**I.3.3** The blood *Sample* is sealed and deposited in the storage device containing the temperature data logger.

### **I.4. Transportation Requirements**

**I.4.1** Blood *Samples* shall be transported in a device that maintains the integrity of *Samples* over time, due to changes in external temperature.

**I.4.2** The transport procedure is the DCO's responsibility. The transport device shall be transported by secure means using a Sample Collection Authority authorized

transport method.

- I.4.3** The integrity of the *Markers* used in the haematological module of the *Athlete Biological Passport* is guaranteed when the Blood Stability Score (BSS) remains below eighty-five (85), where the BSS is computed as:

$$\text{BSS} = 3 * T + \text{CAT}$$

with CAT being the Collection to Analysis Time (in hours), and T the average Temperature (in degrees Celsius) measured by the data logger between *Sample* collection and analysis.

- I.4.4** Within the framework of the BSS, the following table can be used by the DCO/BCO to estimate the maximal transport time to a Laboratory or WADA- Approved Laboratory for the Athlete Biological Passport, called the Collection to Reception Time (CRT), for a given average temperature T:

T [°C]	CRT [h]
15	35
12	41
10	46
9	48
8	50
7	53
6	55
5	58
4	60

- I.4.5** The DCO/BCO shall as soon as possible transport the *Sample* to a Laboratory or WADA- Approved Laboratory for the Athlete Biological Passport.

- I.4.6** The Testing Authority or Sample Collection Authority shall report without delay into ADAMS:

- a) The *Doping Control* form as per Article 4.9.1 b);
- b) The *Athlete Biological Passport* supplementary form, and/or the additional information specific to the *Athlete Biological Passport* collected on a related report form;
- c) In the Chain of Custody, the temperature data logger ID (without any time reference) and the time zone of the *Testing* location in GMT.

## 3.2 Analytical Requirements for the Hematological Module of the *Athlete Biological Passport*

### *WADA Technical Document – TD2021BAR*

Document Number:	TD2021BAR	Version Number:	1.0
Written by:	WADA Science	Approved by:	WADA Executive Committee
Reviewed by:	WADA Laboratory Expert Group		
Date:	21 December 2020	Effective Date:	1 April 2021

### 1.0 Introduction

The purpose of this *Technical Document (TD)* is to harmonize the analysis of *ABP* blood *Samples* collected, both *In-Competition* and *Out-of-Competition*, for the measurement and reporting of individual *Athlete* blood *Markers* within the framework of the hematological module of the *Athlete Biological Passport (ABP)*.

The *International Standard for Laboratories (ISL)* <sup>[1]</sup> is applicable to the analysis of *ABP* blood *Samples* carried out in connection with the measurement of individual *Athlete* blood *Markers* within the framework of the *ABP*. This *TD* describes certain specificities of blood analysis related to the *ABP*.

In order to standardize analytical results in the *ABP*, *ABP* blood *Samples* shall only be analyzed with analyzers of comparable technical characteristics in the dedicated network of laboratories (*i.e.* *WADA*-accredited laboratories or *ABP Laboratories*). The *Analytical Method* for measuring *ABP* blood variables shall be included within the *Laboratory* or *ABP Laboratory's* Scope of ISO/IEC (17025 or 15189) Accreditation, and the *Laboratory* or *ABP Laboratory* shall satisfactorily participate in the relevant *WADA External Quality Assessment Scheme (EQAS)*, as determined by *WADA*, prior to applying the *Analytical Method* to *ABP* blood *Samples*.

*Sample* handling shall be conducted in compliance with the *TD* on *Laboratory Internal Chain of Custody (TD LCOC)* <sup>[2]</sup>.

If not reasonably possible for *ABP* blood *Samples* to be analyzed in a *Laboratory* or *ABP Laboratory* for technical and/or geographical reasons, *ABP* blood *Samples* can be analyzed at a satellite facility of a *Laboratory* or using mobile units operated by a *Laboratory* under their applicable ISO/IEC accreditation (17025 or 15189). Satellite facilities and mobile units shall also be ISO/IEC (17025 or 15189) accredited and participate in the *WADA EQAS* for blood *Markers* for the *ABP* prior to analysis of *ABP* blood *Samples*.

### 2.0 *ABP* blood *Sample* Reception and Timing of Analysis

Upon reception at the *Laboratory* or *ABP Laboratory*, the *ABP* blood *Sample* shall be analyzed as soon as possible and no later than twelve (12) hours after reception unless the *Sample Collection Authority (SCA)* provides specific information regarding the *Sample* collection and transportation conditions (for example, the *SCA* provides a projected time window for analysis during which the projected Blood Stability Score (BSS) should remain acceptable) that would

allow the Laboratory or ABP Laboratory to analyze the *Sample* beyond twelve (12) hours after reception without compromising the *ABP* blood *Sample* validity.

In cases when the Laboratory or ABP Laboratory is unable to analyze the *ABP* blood *Sample* immediately after reception, the Laboratory or ABP Laboratory is responsible for maintaining the *ABP* blood *Sample(s)* at a cool temperature (approximately 4°C) between reception and the start of the analysis. The temperature data logger shall accompany the *ABP* blood *Sample(s)* until homogenization.

The *ABP* blood *Sample* shall not be aliquoted before the *ABP* analysis is satisfactorily conducted. Only after the analysis for the *ABP* has been satisfactorily completed may the Laboratory or ABP Laboratory aliquot the *ABP* blood *Sample* for the performance of other Analytical Testing Procedures (e.g. test for homologous blood transfusion, EPO and agents affecting erythropoiesis).

If there is a Laboratory or ABP Laboratory deviation from the aforementioned procedure, the Laboratory or ABP Laboratory shall proceed with the analysis and report the results into *ADAMS* with a detailed description of the deviation. If the *ABP* blood *Sample* cannot be analyzed, the Laboratory or ABP Laboratory shall report the *Sample* as “Not Analyzed” and provide a description of why it could not be analyzed in *ADAMS*.

### 3.0 Instrument Check

The Laboratory or ABP Laboratory shall maintain an instrument maintenance schedule to ensure proper performance; particularly if an analysis has not been recently conducted and the instrument remains idle for an extended period of time.

The analyst shall ensure that all reagents are within their expiration dates and comply with the reagent manufacturer’s recommendations before performing an analysis. Operational parameters of the instrument (background level, temperature of the incubation chambers, pressure, etc.) shall be verified as compliant with manufacturer’s specifications.

In each analysis session:

- All internal quality controls (QC levels 1, 2 and 3) shall be analyzed twice, following the specifications provided by the manufacturer, prior to the analysis of *Samples*.
- If more than 30 *Samples* are analyzed, at least one internal QC from the manufacturer (either level 1, 2 or 3) shall be analyzed in the middle of the analytical session, and every 30 - 50 *Samples* for larger batches.
- At the end of each analysis session and after all blood *Sample* analyses are completed, one internal QC (either level 1, 2 or 3) shall be analyzed once again to demonstrate the continuous stability of the instrument and the quality of the analyses done.

All results relevant to the *ABP* shall be in agreement with the reference value ranges of the manufacturer. These internal QCs shall be furnished exclusively by the instrument manufacturer and handled in strict accordance with the manufacturer specifications (e.g. expiration dates, storage conditions). The analysis of internal QCs shall be monitored via QC-charts with appropriate control limits.

At least once a month, following the satisfactory analysis of all internal QCs (levels 1, 2 and 3) as described above, one fresh blood sample shall be homogenized for a minimum period of fifteen (15) minutes on an appropriate mixer (e.g. roller mixer). The fresh blood sample shall be analyzed at least seven (7) consecutive times under Repeatability conditions. The Repeatability of the determinations, expressed as coefficients of variation (CV %), shall be below 1.5% for Haemoglobin (HGB) and Haematocrit (HCT), and below 15% for Reticulocyte percentage (RET%).

*[Comment: Samples from Athletes shall not be used as a fresh blood sample to conduct the Repeatability analysis.]*

#### 4.0 External Quality Assessment Scheme (EQAS)

The Laboratories or ABP Laboratories shall participate in and meet the requirements of WADA's EQAS for blood Markers for the ABP. WADA's EQAS program is the only EQAS relevant to the Laboratory's or ABP Laboratory's compliance with the requirements for the analysis of blood Markers within the framework of the hematological module of the ABP (in case of discrepancy with other blood EQAS programs).

All internal QCs (levels 1, 2 and 3) shall be analyzed twice following the specifications provided by the manufacturer prior to the analysis of EQAS samples. All results relevant to the ABP shall be in agreement with the reference value ranges of the manufacturer. The EQAS sample shall be homogenized for a minimum period of fifteen (15) minutes using an appropriate mixer (e.g. roller mixer) prior to analysis. The external QCs shall be analyzed multiple times consecutively (based on the EQAS rules), and the mean results of the following blood variables (full blood count) shall be returned:

Red Blood Cell (Erythrocyte) Count	RBC
Mean Corpuscular Volume	MCV
Haematocrit	HCT
Haemoglobin	HGB
Mean Corpuscular Haemoglobin	MCH
Mean Corpuscular Haemoglobin Concentration	MCHC
White Blood Cell (Leukocyte) Count	WBC
Platelet (Thrombocyte) Count	PLT
Reticulocytes Percentage	RET%

Laboratories or ABP Laboratories may also participate in ring tests with other laboratories (hospitals, clinics, etc.) using the same technology and the same procedure.

#### 5.0 Analysis of ABP Blood Samples

##### 5.1 Temperature Data Logger

The temperature data logger shall be stopped before ABP blood Sample homogenization, upon removal of the ABP blood Sample(s) from the cooling device or refrigerator. The ABP blood

*Sample* shall be homogenized prior to analysis and for a minimum period of fifteen (15) minutes using an appropriate mixer (e.g. roller mixer).

In cases when the temperature data logger accompanies multiple *ABP* blood *Samples*, and these *ABP* blood *Samples* are analyzed in the same batch by the Laboratory or ABP Laboratory, the temperature data logger shall be stopped before the homogenization of the first *ABP* blood *Sample*. The Laboratory shall proceed with the analysis of all *ABP* blood *Samples* associated with the same temperature data logger without delay.

## 5.2 *ABP* Blood *Sample* Analysis

The *ABP* blood *Sample* shall be analyzed twice. The Laboratory's or ABP Laboratory's procedure should minimize the delay between the two analyses. Absolute differences between the two (2) analyses shall be equal or less than ( $\leq$ ) each of the following criteria in order to accept the results:

- 0.1 g/dL for HGB;
- 0.15% for RET% if either the first or second measurement is lower or equal to 1.00%; otherwise 0.25% absolute difference.

The data from the second injection is used to confirm the first injection data. Therefore, if the absolute differences between the results of the analyses are within the criteria above, then only the first injection data is reported into *ADAMS*.

If the absolute differences between the results of the two analyses are greater than ( $>$ ) those defined above, then the *ABP* blood *Sample* shall be analyzed twice again in accordance with Article 5.2. In cases of repeated analysis, the *ABP* blood *Sample* shall be mixed prior to re-analysis using the automated mixing feature of the blood analyzer or by appropriate manual inversion. This reanalysis procedure shall be repeated until the absolute differences between the results of the two (2) most recent analyses are within the criteria specified above.

The requirements for an Initial Testing Procedure (ITP), an "A" Sample Confirmation Procedure (CP) and a "B" Sample CP, as defined in the ISL <sup>[1]</sup>, shall not be applicable to *ABP* blood *Samples* analyzed for the purposes of the *ABP*.

## 6.0 Reporting

### 6.1 Temperature Report

The Laboratory or ABP Laboratory shall promptly submit into *ADAMS* the raw temperature profile report recorded by the temperature data logger. The filename shall consist in the concatenation of the data logger ID with the date of *Sample* reception by the Laboratory or ABP Laboratory ("YYYY-MM-DD" in local time) separated by an underscore. For example, for a data logger ID "KG34V10" and a date of *Sample* reception "2015-03-25", the Laboratory or ABP Laboratory shall report the temperature profile under the filename "KG34V10\_2015-03-25.txt". The Laboratory or ABP Laboratory shall report the temperature profile into *ADAMS* before the test results of the *Sample*, when temperature data can be retrieved from the logger.

[Comment: Where the Sample meets the requirements of the ISTI Annex I, Article I.2.7, and is analyzed at the Sample collection site without delay, a temperature data logger is not necessary and the Laboratory shall proceed to reporting the test results of the Sample.

In cases that the Laboratory is unable to upload a suitable temperature profile report from the temperature data logger into ADAMS, the Laboratory shall proceed to upload the test results of the relevant Sample(s).]

## 6.2 Reporting ABP Blood Sample Test Results

The Laboratory or ABP Laboratory should report the ABP blood Sample test results as soon as possible and within three (3) days after Sample reception. The following shall be reported into ADAMS:

- Status (“Submitted” or “Not Analyzed”);
- ABP blood Sample code;
- Type of test (*Out-of-Competition / In-Competition*);
- Sport and discipline;
- Date and time of receipt of the ABP blood Sample;
- Date and time of analysis of the ABP blood Sample;
- The name of the Testing Authority;
- The name of the Sample Collection Authority;
- Type of Sample (blood Passport);
- Type of analyzer;
- Test results (other variables may be included for quality purposes):

Blood Variable		Unit(s)
Haemoglobin	HGB	g/dL
Hematocrit	HCT	%
Immature Reticulocyte Fraction	IRF	%
Mean Corpuscular Haemoglobin	MCH	pg
Mean Corpuscular Haemoglobin Concentration	MCHC	g/dL
Mean Corpuscular Volume	MCV	fL
OFF-Score	-	-
Platelets	PLT	10 <sup>3</sup> /μL
Red Blood Cell Distribution Width	RDW-SD	fL
Red Blood Cells	RBC	10 <sup>6</sup> /μL
Reticulocytes – in absolute number	RET	10 <sup>6</sup> /μL
Reticulocytes Percentage	RET%	%
White Blood Cells	WBC	10 <sup>3</sup> /μL

- Include a comment describing any relevant deviation as part of the ABP blood Sample’s ADAMS record.

## 7.0 References

[1] The World Anti-Doping *Code International Standard for Laboratories* (ISL).

[2] WADA *Technical Document* TD LCOC: *Laboratory Internal Chain of Custody*.

[*Comment: Current versions of WADA ISL and Technical Documents may be found at <https://www.wada-ama.org/en/what-we-do/science-medical/laboratories>* ]

### 3.3 Measurement and Reporting of Endogenous Anabolic Androgenic Steroids (EAAS) Markers of the Urinary Steroid Profile

#### *WADA Technical Document – TD2021EAAS*

Document Number:	TD2021EAAS	Version Number:	1.0
Written by:	WADA Science/EAAS Working Group	Approved by:	WADA Executive Committee
Reviewed by:	WADA <u>Laboratory Expert Group</u>		
Date:	21 December 2020	Effective Date:	1 April 2021

#### 1.0 Introduction

The purpose of this *Technical Document (TD)* is to harmonize the measurement and reporting of the “steroid profile” of urine *Samples* in support of the steroidal module of the *Athlete Biological Passport (ABP)* (the steroidal Passport).

##### 1.1 The Steroid Profile

The measurement of steroidal *Markers* [concentrations and ratios of defined Endogenous Anabolic Androgenic Steroids (EAAS)] in a urine *Sample* form the steroid profile for that *Sample* (see Table 1).

The steroid profiles of a series of urine *Samples* collected from an *Athlete* over a period of time constitute the steroidal Passport of that *Athlete*.

The administration of synthetic forms of EAAS can alter one or more of the *Markers* of the urinary steroid profile, resulting in increased or decreased concentrations and/or ratios of specific pairs of steroid *Markers* <sup>[1-3]</sup>. This effect forms the basis for the use of the steroidal Passport as a tool for the detection of doping with EAAS, in particular testosterone (T), its precursors (for example, 4-androstenediol, androstenedione and prasterone), its active *Metabolite* [dihydrotestosterone (DHT)], or its epimer epitestosterone (E).

The steroidal module of the *ABP* utilizes the Adaptive Model in *ADAMS* to trigger *Atypical Passport Findings (ATPFs)*, which can lead to the performance of Confirmation Procedures (CP), *Target Testing* of an *Athlete*, or to establish *Use of a Prohibited Substance* and/or *Prohibited Method* as per *Code Article 2.2* (see *International Standard for Results Management, Annex C* <sup>[4]</sup>).

##### 1.2 Procedure for Determination of the Steroid Profile

Each urine *Sample* shall be analyzed to determine its steroid profile. The determination and reporting of a *Sample*’s steroid profile follows a two-step procedure:

- i. An Initial Testing Procedure (ITP) is conducted to estimate the steroid profile of the *Sample*, and

- ii. A subsequent CP is performed when the reported steroid profile constitutes an *ATPF*, as determined by the Adaptive Model, or upon request from the Athlete Passport Management Unit (APMU), the Testing Authority or *WADA*.

**Table 1.** *Markers of the Urinary Steroid Profile.*

Type of Marker	Steroid Profile Markers	Determination
<b>Concentrations of Steroids</b>	<ul style="list-style-type: none"> <li>- Androsterone (A);</li> <li>- Etiocholanolone (Etio);</li> <li>- 5<math>\alpha</math>-Androstane-3<math>\alpha</math>,17<math>\beta</math>-diol (5<math>\alpha</math>Adiol);</li> <li>- 5<math>\beta</math>-Androstane-3<math>\alpha</math>,17<math>\beta</math>-diol (5<math>\beta</math>Adiol);</li> <li>- Testosterone (T); and</li> <li>- Epitestosterone (E).</li> </ul>	Determined by the <u>Laboratory</u> by GC-MS <sup>n</sup> from the combination of the free steroid fraction and the conjugated fraction released after hydrolysis with $\beta$ -glucuronidase from <i>E. coli</i> .
<b>Ratios of Steroids</b>	- T/E	As reported by the <u>Laboratory</u> in <i>ADAMS</i> .
	<ul style="list-style-type: none"> <li>- A/T;</li> <li>- A/Etio;</li> <li>- 5<math>\alpha</math>Adiol/5<math>\beta</math>Adiol; and</li> <li>- 5<math>\alpha</math>Adiol/E</li> </ul>	Automatically computed in <i>ADAMS</i> from respective steroid concentrations after the reporting of the steroid profile by the <u>Laboratory</u> .

### 1.3 Factors Impacting the Steroid Profile

In addition to the effects mediated by the administration of EAAS, alteration of the urinary steroid profile can occur for a number of other reasons including, but not limited to, the following factors [1-3]:

- Intake of alcohol (ethanol);
- The administration of other anabolic androgenic steroids (e.g. stanozolol);
- The administration of human chorionic gonadotrophin (hCG) in males;
- The administration of aromatase inhibitors and anti-estrogenic substances;
- The administration of inhibitors of 5 $\alpha$ -reductase (e.g. finasteride, dutasteride);
- The administration of ketoconazole or other similar compounds (e.g. fluconazole, miconazole);
- The use of masking agents (e.g. probenecid) and diuretics;
- Microbial activity;
- *Sample* manipulation.

## 2.0 Initial Testing Procedure (ITP)

### 2.1 ITP Method Requirements

The quantification of the *Markers* of the steroid profile shall be based on gas chromatography combined with mass spectrometry (GC-MS<sup>n</sup>;  $n \geq 1$ ).

**Table 2.** Requirements of the ITP for Quantification of the *Markers* of the Steroid Profile.

2.1.1 <u>ITP</u> Validation Requirements								
<b>Range of the Method</b>	Shall cover the ranges of <i>Marker</i> concentrations normally found in males and females.							
<b>Enzymatic Hydrolysis</b>	Assess the efficiency of the enzymatic hydrolysis using $\beta$ -glucuronidase from <i>E. coli</i>							
<b>Derivatization</b>	Assess the efficiency of the trimethylsilyl (TMS) derivatization							
<b><u>Limits of Quantification (LOQ)</u></b>	The <u>LOQ</u> shall be determined during method validation as the lowest concentration that can be measured with an $u_c$ (%) not greater than ( $\leq$ ) 30% and shall meet the following criteria: <ul style="list-style-type: none"> <li>• T, E <math>\leq</math> 1 ng/mL;</li> <li>• 5<math>\alpha</math>Adiol, 5<math>\beta</math>Adiol <math>\leq</math> 10 ng/mL;</li> <li>• A, Etio <math>\leq</math> 500 ng/mL</li> </ul>							
<b><u>Measurement Uncertainty, <math>u_c</math> (%)</u></b>	<b>Level</b>	<b>A</b>	<b>Etio</b>	<b>T</b>	<b>E</b>	<b>Adiols (5<math>\alpha</math>-, 5<math>\beta</math>-)</b>	<b>T/E</b>	
	The estimated $u_c$ (%) shall be not greater than ( $\leq$ ) the $u_{c\_Max}$ (%) value given below							
	<b>at <u>LOQ</u></b>	$\leq$ 30%						
	<b>at 5 x <u>LOQ</u></b>	$\leq$ 20%				$\leq$ 25%		
	<b>(T, E) &gt; 5 ng/mL</b>							$\leq$ 15%
<b>(T, E) <math>\leq</math> 5 ng/mL</b>							$\leq$ 30%	
2.1.2 <u>ITP</u> Analysis Requirements								
<b><i>Sample</i></b>	The <u>ITP</u> for the quantification of the <i>Markers</i> of the steroid profile shall be conducted on a single <u>Aliquot</u> . When needed, the volume of the <u>Aliquot</u> may be adjusted as a function of its specific gravity (SG) and of the sex of the <i>Athlete</i> .							
<b>Calibration</b>	Calibration standard(s) or a calibration curve shall be included in each sequence of analysis.							

<b>Quality Control</b>	At least two (2) quality control (QC) urine samples containing representative low and high concentrations of the <i>Markers</i> of the steroid profile shall be included in each sequence of analysis.
<b>Enzymatic Hydrolysis</b>	Purified $\beta$ -glucuronidase from <i>E. coli</i> shall be used for the hydrolysis of the glucuroconjugated urinary steroids, and the completeness of hydrolysis shall be monitored in each <u>Aliquot</u> with isotopically labeled A-glucuronide (or an equivalent scientifically recognized alternative). <i>H. pomatia</i> mixtures shall not be used.
<b>Derivatization</b>	The <i>Markers</i> of steroid profile shall be analyzed as TMS derivatives (TMS enol ethers and/or TMS ethers). Completeness of the derivatization shall be controlled in each <u>Aliquot</u> through the monitoring of mono-O-TMS vs. di-O-TMS derivative of A.
<b>T/E Ratio</b>	The T/E ratios shall be determined from the ratios of chromatographic peak areas or peak heights after correction against a calibrator or a calibration curve.
<b>Factors Impacting the Steroid Profile</b>	The <u>Laboratory</u> shall: <ul style="list-style-type: none"> <li>• Monitor for signs of microbial activity [e.g. presence of indicators of <math>3\alpha</math>-hydroxysteroid dehydrogenase (HSD) activity]; <i>[Comment: The direct enzymatic hydrolysis of urine Samples may increase the effects of microbial contamination.]</i></li> <li>• Test for the presence of conjugated <i>Metabolite(s)</i> of ethanol [e.g. ethanol glucuronide (EtG)], <math>5\alpha</math>-reductase inhibitors (e.g. finasteride, dutasteride) and ketoconazole (and similar substances).</li> </ul>

## 2.2 Reporting the *Sample's* Steroid Profile from the ITP

Following the performance of the ITP, the Laboratory shall report in *ADAMS* the steroid profile for each *Sample* analyzed.

The Laboratory shall report in *ADAMS*:

- i. The SG of the *Sample*, as determined by the Laboratory (see TD DL <sup>[5]</sup>);
- ii. The uncorrected concentrations of T, E, A, Etio,  $5\alpha$ Adiol and  $5\beta$ Adiol, and the T/E ratio;

*[Comment: When the ITP measurement of a steroid profile Marker is not possible due to, for example, dilution, unusual matrix interferences, inhibition of the enzymatic hydrolysis or incomplete derivatization, the Laboratory should repeat the analysis with an alternative *Sample* preparation procedure (e.g. changing Aliquot volumes, application of solid phase extraction, or extraction with a different solvent).*

*If, however, a Marker of the steroid profile cannot be quantified, the concentration of the affected Marker shall be reported as "-1". The Laboratory shall make a comment in the Test Report on why this Marker could not be quantified (e.g. < LOQ, incomplete derivatization).*

*When the chromatographic peak signal for a Marker cannot be detected (i.e. is below the detection capability of the assay), the concentration of the Marker shall be reported as "-2" (See Table 3 for reporting of specific situations for [T], [E], and T/E).*

*The Laboratory may also provide information on other steroidal parameters such as prasterone (DHEA), dihydrotestosterone (DHT) and  $6\alpha$ -hydroxy-androstenedione ( $6\alpha$ -OH-AD) at the request of the Testing Authority, Results Management Authority or the APMU.]*

- 
- iii. Any signs of microbial activity in the *Sample*, e.g. ratios of 5 $\alpha$ -androstanedione (5 $\alpha$ AND) to A and 5 $\beta$ -androstanedione (5 $\beta$ AND) to Etio, as determined from the respective steroid concentrations;
- iv. The presence or absence in the *Sample* of substance(s) that may alter the steroid profile (see Article 1.3). The Laboratory shall report the estimated levels of:
- EtG if  $\geq 5$   $\mu\text{g/mL}$ ;
  - Carboxy-finasteride if  $\geq 5$  ng/mL;
  - 4-hydroxy- and/or 6-hydroxy-dustasteride if  $\geq 5$  ng/mL;
  - Ketoconazole if  $\geq 100$  ng/mL;
  - Fluconazole if  $\geq 500$  ng/mL;
  - Miconazole if  $\geq 1,000$  ng/mL.

### 2.2.1 Validity of the *Sample* Steroid Profile

The validity of the *Sample* will be determined automatically upon reporting of the steroid profile in ADAMS. A *Sample* will be invalid only when the *Sample* shows signs of extensive degradation, as determined by:

- 5 $\alpha$ AND/A  $\geq 0.1$ , and/or
- 5 $\beta$ AND/Etio  $\geq 0.1$

*[Comment: In addition, following the reporting of the steroid profile in ADAMS by the Laboratory, the *Sample* may be evaluated as "invalid" by the APMU upon review of the steroid profile data, for example, by considering the presence of substances that may alter the steroid profile in the *Sample*.]*

**Table 3.** Summary of conditions for reporting T and E concentrations and T/E ratio.

Concentration of T	Concentration of E	T/E ratio
Chromatographic peak signal of T measured at or above ( $\geq$ ) the <u>LOQ</u> .  $[T] \geq \text{LOQ}_{(T)}$  <b>Report T as measured</b>	Chromatographic peak signal of E measured at or above ( $\geq$ ) <u>LOQ</u> .  $[E] \geq \text{LOQ}_{(E)}$ <b>Report E as measured.</b>	<b>Report T/E</b> (as determined by the <u>Laboratory</u> from corrected peak heights/areas)
	Chromatographic peak signal of E detected, but below ( $<$ ) <u>LOQ</u> .  $\text{LOD}_{(E)} \leq [E] < \text{LOQ}_{(E)}$ <b>Report E as “-1”</b>	
	Chromatographic peak signal of E not detected.  $[E] < \text{LOD}_{(E)}$ <b>Report E as “-2”</b>	<b>Report T/E as “-1”</b> Report the <u>LOD</u> <sub>(E)</sub>  <i>Comment in ADAMS: T/E ratio could not be measured accurately because E could not be detected.</i>
Chromatographic peak signal of T detected, but below ( $<$ ) the <u>LOQ</u> .  $\text{LOD}_{(T)} \leq [T] < \text{LOQ}_{(T)}$  <b>Report T as “-1”</b>	Chromatographic peak signal of E measured at or above ( $\geq$ ) <u>LOQ</u> .  $[E] \geq \text{LOQ}_{(E)}$ <b>Report E as measured</b>	<b>Report T/E</b> (as determined by the <u>Laboratory</u> from corrected peak heights/areas)
	Chromatographic peak signal of E detected, but below ( $<$ ) <u>LOQ</u> .  $\text{LOD}_{(E)} \leq [E] < \text{LOQ}_{(E)}$ <b>Report E as “-1”</b>	
	Chromatographic peak signal of E not detected.  $[E] < \text{LOD}_{(E)}$ <b>Report E as “-2”</b>	<b>Report T/E as “-1”</b>  <i>Comment in ADAMS: T/E ratio could not be measured accurately because the concentration of T could not be measured, and E could not be detected</i>
Chromatographic peak signal of T not detected.  $[T] < \text{LOD}_{(T)}$  <b>Report T as “-2”</b>	Chromatographic peak signal of E measured at or above ( $\geq$ ) <u>LOQ</u> .  $[E] \geq \text{LOQ}_{(E)}$ <b>Report E as measured</b>	<b>Report T/E as “-1”</b> Report the <u>LOD</u> <sub>(T)</sub>  <i>Comment in ADAMS: T/E ratio could not be measured accurately because T could not be detected</i>
	Chromatographic peak signal of E detected but below ( $<$ ) <u>LOQ</u> .  $\text{LOD}_{(E)} \leq [E] < \text{LOQ}_{(E)}$ <b>Report E as “-1”</b>	<b>Report T/E as “-1”</b> Report the <u>LOD</u> <sub>(T)</sub>  <i>Comment in ADAMS: T/E ratio could not be measured because T could not be detected, and E could not be measured.</i>
	Chromatographic peak signal of E not detected.  $[E] < \text{LOD}_{(E)}$ <b>Report E as “-2”</b>	<b>Report T/E as “-2”</b> Report the <u>LOD</u> <sub>(E)</sub> and <u>LOD</u> <sub>(T)</sub>  <i>Comment in ADAMS: T/E ratio could not be measured because T and E could not be detected.</i>

### 3.0 Confirmation Procedures (CP)

The CP for the EAAS *Markers* include the GC-MS<sup>n</sup> ( $n \geq 1$ ) identification (in compliance with the TD IDCR <sup>[6]</sup>) and quantification, as well as the GC/C/IRMS analysis <sup>[7]</sup> of the *Marker(s)* of the steroid profile.

In addition, the Laboratory shall confirm the presence or absence of factors impacting the steroid profile (see Article 1.3).

#### 3.1 CP Requests (CPRs)

##### 3.1.1 CPRs triggered by *Atypical Passport Findings (ATPF)* through ADAMS

Once the *Sample's* steroid profile data are entered in ADAMS and matched with an *Athlete*, the Adaptive Model automatically updates the steroidal Passport. If an *ATPF* is identified based on an abnormally high T/E value, a CP request (*ATPF-CPR*) is triggered and sent automatically to Laboratories through ADAMS.

Upon receipt of an *ATPF-CPR*, the Laboratory shall proceed with the CP of the steroid profile as soon as possible, unless the presence of ethanol or other factors impacting the steroid profile has been detected in the *Sample*. In such cases, the Laboratory shall receive, within fifteen (15) days from the *ATPF-CPR* notification, an advice from the Passport Custodian or the Testing Authority (or Results Management Authority, if different) on whether to proceed or not with the CP of the *Sample's* steroid profile.

*[Comment: In the absence of communication from the Passport Custodian or the Testing Authority (or Results Management Authority) within fifteen (15) days from the *ATPF-CPR* notification, the Laboratory shall proceed with the CP of the steroid profile (see Article 3.2)].*

Any justification from the Passport Custodian or the Testing Authority (or Results Management Authority) not to proceed with the CP shall be provided in writing and in compliance with the TD APMU <sup>[8]</sup>.

*[Comment: In cases when the Laboratory is instructed by the Passport Custodian or the Testing Authority (or Results Management Authority) not to perform the CP, the Laboratory shall update the ADAMS Test Report for the *Sample* with a comment stating that the Passport Custodian, Testing Authority (or Results Management Authority) requested not to perform the CP, and the reasons given.]*

When the Laboratory receives an *ATPF-CPR* for a *Sample* for which *Adverse Analytical Finding(s)* (AAF) have been reported for other *Prohibited Substance(s)* or *Method(s)*, the Laboratory shall consult the Testing Authority (or Results Management Authority, if different) about the need to conduct the CP for the *Markers* of the steroid profile.

##### 3.1.2 CPRs from the APMU, the Testing Authority (or Results Management Authority, as applicable) or WADA.

The Adaptive Model will also determine abnormal values or sequences of the other ratios of the "steroid profile" (A/T, A/Etio, 5 $\alpha$ Adiol/5 $\beta$ Adiol, 5 $\alpha$ Adiol/E). However, in such cases the Laboratory will not receive an automatic "*ATPF-CPR*" notification through ADAMS. Instead, the APMU will advise the Testing Authority (or Results Management Authority, if different) on whether the *Sample* shall be subjected to CP. Therefore, in these cases the Laboratory shall receive a written

request from the Testing Authority (or Results Management Authority, if different) before proceeding with the CP.

In the absence of an ATPF-CPR, requests for CP can be made also by the Testing Authority (or Results Management Authority, if different), the APMU \*, or WADA.

\* where the respective client of the APMU has agreed to bestow such authority to the APMU.

### 3.2 CP Test Methods

#### 3.2.1 CP of Steroid Profile *Markers* by GC-MS<sup>n</sup>

The Laboratory shall quantify all the *Markers* of the steroid profile in one Aliquot by a validated Fit-for-Purpose GC-MS<sup>n</sup> ( $n \geq 1$ ) quantification method. Identification (in compliance with the TD IDCR <sup>[6]</sup>) of the *Markers* that triggered the CP shall be performed as well.

- In every case, the Laboratory shall confirm quantitatively all the *Markers* of the steroid profile before proceeding with the GC/C/IRMS analysis;

*[Comment: This requirement does not apply if the Testing Authority (or Results Management Authority, as applicable) has authorized the Laboratory to proceed directly to GC/C/IRMS analysis without a need for a quantitative confirmation of the steroid *Markers* (for example, in cases of limited Sample volume).*

*For T/E values, only T needs to be confirmed if E is not detected or the volume of the Sample is not sufficient.]*

- In the case of an ATPF-CPR for an abnormally high T/E ratio, GC/C/IRMS analysis is not mandatory when the confirmed T/E value is below the confirmation T/E cut-off calculated by the Adaptive Model and provided within the ATPF-CPR notification received from ADAMS;
- For other CP requests, when the steroid profile CP does not confirm the ITP values that triggered the CP (e.g.  $5\alpha$ Adiol/E value), taking into consideration the expanded uncertainty of the measurement ( $U_{95\%}$ ,  $k = 2$ ), the Laboratory shall consult the Testing Authority to determine if the GC/C/IRMS analysis is necessary. In the event that GC/C/IRMS analysis is deemed unnecessary, the Laboratory shall update the ADAMS report for the *Sample* with the confirmed values of all the *Markers* of the steroid profile and include a comment that GC/C/IRMS analysis was not necessary.

*[Comment: for ratios other than the T/E, the  $u_c$  (%) of the ratio shall be calculated by propagation of uncertainties of the corresponding Marker concentrations.]*

The same analytical requirements presented in Table 2 for the ITP shall apply for the GC-MS<sup>n</sup> CP, with the following modifications:

- GC-MS<sup>n</sup> CP Validation Requirements
  - For determinations of A, Etio,  $5\alpha$ Adiol and  $5\beta$ Adiol, the  $u_c$  (%) shall be not greater than ( $\leq$ ) 15% when the concentrations are five times (5x) the respective LOQ;
  - For determinations of T, E and T/E ratios, the  $u_c$  (%) shall be not greater than ( $\leq$ ) 15% when the concentrations of T and E are greater than ( $>$ ) 5 ng/mL.
- GC-MS<sup>n</sup> CP Analysis Requirements

- A Solid Phase Extraction (SPE) shall be performed prior to the enzymatic hydrolysis of the *Sample*;
- Calibration standard(s) and at least two (2) QC urine samples containing representative low and high levels of the *Markers* of the steroid profile shall be included.

### 3.2.2 GC/C/IRMS CP

Technical and reporting requirements for the GC/C/IRMS CP are specified in the TD IRMS <sup>[7]</sup>.

When an *AAF* is reported for the *Marker(s)* of the steroid profile based on the results of a GC/C/IRMS analysis performed on the “A” *Sample*, only the GC/C/IRMS analysis, including the identification of the relevant *Markers* (target compounds and endogenous reference compounds) shall be repeated during the “B” *Sample CP*.

## 3.3 Reporting Results from the CP

### 3.3.1 “A” *Sample*

Following the CP performed for the steroid profile on the “A” *Sample*, the Laboratory shall report in *ADAMS*:

- i. The SG of the *Sample* (determined from a new Aliquot of the “A” *Sample*);
- ii. The confirmed value of the *Markers* of the steroid profile (concentrations, T/E value), without adjustment for the SG of the *Sample*;
- iii. The associated  $u_c$  (expressed in units);
- iv. The GC/C/IRMS confirmation results, if performed (see Articles 3.2.1 and 3.2.2 and TD IRMS <sup>[7]</sup>). The Laboratory shall update the Test Report for the *Sample* in *ADAMS* (as *AAF*, *Atypical Finding (ATF)*, or Negative Finding) based on the results of the GC/C/IRMS CP;
- v. The confirmed results (presence/absence) for signs of microbial activity:  $5\alpha\text{AND}/A$ ,  $5\beta\text{AND}/\text{Etio}$ , and  $T_{\text{free}}/T_{\text{total}}$ ; based on concentrations;

*[Comment: In addition to the determination of the  $5\alpha\text{AND}/A$  and  $5\beta\text{AND}/\text{Etio}$  ratios as signs of microbial contamination, the determination during the CP of an elevated ratio of free Testosterone to total Testosterone ( $T_{\text{free}} / T_{\text{total}} > 0.05$ ) will also invalidate (the steroid profile of) the *Sample*. However, this shall not preclude the performance of the GC/C/IRMS CP or invalidate its results.]*

- vi. The presence or absence in the *Sample* of substance(s) that do not constitute an *AAF* but may alter the steroid profile (see Article 1.3): if detected in the *Sample*, the Laboratory shall report the confirmed estimated levels of EtG,  $5\alpha$ -reductase inhibitors and -azoles as specified in Article 2.2.1 (without the need to report the  $u_c$  for these determinations).

### 3.3.2 “B” *Sample*

Following the performance of the GC/C/IRMS CP for the steroid profile on the “B” *Sample*, the Laboratory shall report the GC/C/IRMS confirmation results (see Article 3.3.1 and TD IRMS <sup>[7]</sup>) in *ADAMS*.

[Comment: If the Sample has not been reported as an AAF for the Marker(s) of the steroid profile based on the results of the GC/C/IRMS analysis, but the steroid profile CP by GC-MS<sup>n</sup> has been requested for the “B” Sample, then the Laboratory shall report in ADAMS the results of the “B” confirmation of the steroid profile as described for the “A” Sample in Article 3.3.1.]

#### 4.0 Reporting Sample Manipulation (*Tampering or Attempted Tampering*)

*Tampering or Attempted Tampering* aims to alter the integrity and validity of Samples collected during *Doping Control*, including, but not limited to Sample substitution with another fluid and urine exchange and/or adulteration (e.g. addition of proteases to Sample).

[Comment: the substitution of an Athlete’s urine Sample with the urine of another individual (urine exchange) can be uncovered using the steroidal Passport and confirmed by DNA analysis across multiple Samples, as described in the TD APMU <sup>[8]</sup>.]

In cases when a Sample is not consistent with human urine (e.g. SG  $\leq$  1.001, creatinine  $\leq$  5 mg/dL <sup>[9]</sup>, non-physiological salt concentration, abnormal pH values, absence or abnormally low levels of endogenous steroids, corticosteroids, proteins, etc.), the Laboratory shall:

- i. Report the finding as an AAF for *Tampering or Attempted Tampering* (class M2.1 of the *Prohibited List*) if the Laboratory can determine the general nature/type of the adulterated Sample, which is not consistent with human urine (e.g. water, liquor, synthetic urine);

OR

- ii. Report the finding as an ATF for *Tampering or Attempted Tampering* and include a comment in ADAMS advising the Testing Authority to perform further investigations (e.g. additional analyses on the Sample, *Target Testing the Athlete*).

#### 5.0 References

- [1] Mareck U *et al.* Factors influencing the steroid profile in doping control analysis. *J Mass Spectrom.* **43**(7):877-91, 2008.
- [2] Ayotte C. Detecting the administration of endogenous anabolic androgenic steroids. *Handb Exp Pharmacol.* **195**:77-98, 2010.
- [3] Kuuranne T, Saugy M, Baume N. Confounding factors and genetic polymorphism in the evaluation of individual steroid profiling. *Br J Sports Med.* **48**(10): 848-55, 2014.
- [4] The World Anti-Doping Code *International Standard for Results Management*.
- [5] WADA *Technical Document* TD DL: *Decision Limits for the Confirmatory Quantification of Exogenous Threshold Substances* by Chromatography-based Analytical Methods.
- [6] WADA *Technical Document* TD IDCR: *Minimum Criteria for Chromatographic-Mass Spectrometric Confirmation of the Identity of Analytes for Doping Control Purposes*.
- [7] WADA *Technical Document* TD IRMS: *Detection of Synthetic Forms of Prohibited Substances by GC/C/IRMS*.
- [8] WADA *Technical Document* TD APMU: Athlete Passport Management Unit – Requirements and Procedures.
- [9] Cook J D *et al.* The Characterization of Human Urine for Specimen Validity Determination in Workplace Drug Testing: A Review. *J Anal Toxicol* **24**: 579-588, 2000

[Comment: Current versions of WADA Technical Documents may be found at <https://www.wada-ama.org/en/what-we-do/science-medical/laboratories> ]

### 3.4 Results Management Requirements and Procedures for the Athlete Biological Passport (ISRM Annex C)

#### C.1 Administrative Management

C.1.1 The requirements and procedures described in this Annex apply to all modules of the *Athlete Biological Passport* except where expressly stated or implied by the context.

C.1.2 These processes shall be administered and managed by an Athlete Passport Management Unit on behalf of the Passport Custodian. The Athlete Passport Management Unit will initially review profiles to facilitate targeting recommendations for the Passport Custodian when appropriate or refer to the Experts as required. Management and communication of the biological data, Athlete Passport Management Unit reporting and Expert reviews shall be recorded in *ADAMS* and be shared by the Passport Custodian with other *Anti-Doping Organizations* with Testing Authority over the *Athlete* to coordinate further Passport Testing as appropriate. A key element for *Athlete Biological Passport* management and communication is the Athlete Passport Management Unit report in *ADAMS*, which provides an overview of the current status of the *Athlete's Passport* including the latest targeting recommendations and a summary of the Expert reviews.

C.1.3 This Annex describes a step-by-step approach to the review of an *Athlete's Passport*:

- a) The review begins with the application of the Adaptive Model.
- b) In case of an *Atypical Passport Finding* or when the Athlete Passport Management Unit considers that a review is otherwise justified, an Expert conducts an initial review and returns an evaluation based on the information available at that time.
- c) In case of a "Likely doping" initial review, the Passport is then subjected to a review by three (3) Experts including the Expert who conducted the initial review.
- d) In case of a "Likely doping" consensus of the three (3) Experts, the process continues with the creation of an Athlete Biological Passport Documentation Package.
- e) An *Adverse Passport Finding* is reported by the Athlete Passport Management Unit to the Passport Custodian if the Experts' opinion is maintained after review of all information available at that stage, including the Athlete Biological Passport Documentation Package.
- f) The *Athlete* is notified of the *Adverse Passport Finding* and offered the opportunity to provide explanations.
- g) If after review of the explanations provided by the *Athlete*, the Experts maintain their unanimous conclusion that it is highly likely that the *Athlete Used a Prohibited Substance* or a *Prohibited Method*, an anti-doping rule violation is asserted against the *Athlete* by the Passport Custodian.

## C.2 Initial Review Phase

### C.2.1 Review by the Adaptive Model

**C.2.1.1.** In *ADAMS*, the Adaptive Model automatically processes data on the biological *Markers* of the *Athlete Biological Passport*. These *Markers* include primary *Markers* that are defined as the most specific to doping and secondary *Markers* that provide supporting evidence of doping in isolation or in combination with other *Markers*. The Adaptive Model predicts for an individual an expected range within which a series of *Marker* values falls assuming a normal physiological condition. Outliers correspond to those values outside of the 99%-range, from a lower limit corresponding to the 0.5<sup>th</sup> percentile to an upper limit corresponding to the 99.5<sup>th</sup> percentile (1:100 chance or less that this result is due to normal physiological variation). A specificity of 99% is used to identify both haematological and steroidal *Atypical Passport Findings*. In the case of sequence deviations (sequence *Atypical Passport Findings*), the applied specificity is 99.9% (1:1000 chance or less that this is due to normal physiological variation).

**C.2.1.2.** An *Atypical Passport Finding* is a result generated by the Adaptive Model in *ADAMS* which identifies either a primary *Marker(s)* value(s) as being outside the *Athlete's* intra-individual range or a longitudinal profile of a primary *Marker* values (sequence deviations) as being outside expected ranges, assuming a normal physiological condition. An *Atypical Passport Finding* requires further attention and review.

**C.2.1.3.** The *Athlete Passport Management Unit* may also submit a Passport to the Expert when there is no *Atypical Passport Finding* (see C.2.2.4 below).

**C.2.1.4.** *Atypical Passport Finding* – Haematological Module

**C.2.1.4.1.** For the Haematological Module, the Adaptive Model automatically processes in *ADAMS* two primary *Markers*, haemoglobin concentration (HGB) and stimulation index OFF-score (OFFS), and two secondary *Markers*, the reticulocyte percentage (RET%) and the Abnormal Blood Profile Score (ABPS). An *Atypical Passport Finding* is generated when a HGB and /or OFFS value of the last test falls outside the expected intra-individual ranges. Furthermore, the longitudinal profile composed of (up to) the last five valid HGB and/or OFFS values is also considered as an *Atypical Passport Finding* when deviating from the expected ranges, as determined by the Adaptive Model (sequence *Atypical Passport Finding*). An *Atypical Passport Finding* is only generated by the Adaptive Model based on values of the primary *Markers* HGB and OFFS or the sequence thereof.

**C.2.1.4.2.** In case of an *Atypical Passport Finding* the *Athlete Passport Management Unit* shall advise the *Results Management Authority* (or *Testing Authority* as applicable) in the *Athlete*

Passport Management Unit report, or via the Passport Custodian where appropriate, on whether the *Sample*, or any accompanying urine *Sample*, should be subjected to analysis for Agents Affecting Erythropoiesis. The Athlete Passport Management Unit should also provide recommendations for Agents Affecting Erythropoiesis analysis when the Adaptive Model detects an abnormality in the secondary *Markers* RET% and/or ABPS.

#### **C.2.1.5. Atypical Passport Finding – Steroidal Module**

**C.2.1.5.1** For the Steroidal Module, the Adaptive Model automatically processes in ADAMS one primary *Marker*, the T/E ratio, and four (4) secondary *Markers*, the ratios A/T, A/Etio, 5 $\alpha$ Adiol/5 $\beta$ Adiol and 5 $\beta$ Adiol/E.

**C.2.1.5.2** Ratios coming from a *Sample* that showed signs of heavy microbial degradation, and ratios for which one or both of the concentrations were not measured accurately by the Laboratory as established in the *Technical Document* for Endogenous Anabolic Androgenic Steroids (TDEAAS), shall not be processed by the Adaptive Model. In the case where the Laboratory reports a confounding factor that may otherwise cause an alteration in the steroid profile, such as the presence of ethanol glucuronide in the *Sample*, the Athlete Passport Management Unit shall evaluate whether the steroid profile can still be considered as valid and processed by the Adaptive Model and the *Sample* be subjected to a Confirmation Procedure (see TDEAAS).

**C.2.1.5.3** An *Atypical Passport Finding* is generated when a value of the T/E ratio falls outside the expected intra-individual ranges. In addition, the “*longitudinal steroid profile*” composed of (up to) the last five (5) valid values of the T/E ratio is also considered as atypical when deviating from the expected ranges, as determined by the Adaptive Model (sequence *Atypical Passport Finding*).

**C.2.1.5.4** In the case of a “*longitudinal steroidal profile*”, an *Atypical Passport Finding* caused by an atypically high T/E value will trigger an *Atypical Passport Finding Confirmation Procedure* Request notification through ADAMS as established in the TDEAAS. When the Adaptive Model determines an abnormality in any of the other ratios of the “*steroid profile*” (A/T, A/Etio, 5 $\alpha$ Adiol/5 $\beta$ Adiol and 5 $\beta$ Adiol/E), the Athlete Passport Management Unit should advise the Results Management Authority (or Testing Authority as applicable) in the Athlete Passport Management Unit report, or via the Passport Custodian where appropriate, on whether the *Sample* should be subjected to a Confirmation Procedure.

### C.2.1.6. Suspicious Steroid Profiles – Steroidal Module

**C.2.1.6.1** If the *Sample* constitutes the first and unique result in a Passport, or if the *Sample* cannot be matched to a *Doping Control Form* in *ADAMS*, *ADAMS* will flag the result as a Suspicious Steroid Profile (SSP) if the steroid profile of the *Sample* meets any of the SSP criteria established in the TD EAAS, and the Laboratory and the Testing Authority will receive an SSP-Confirmation Procedure Request (CPR) notification from *ADAMS*. In such cases, the Testing Authority, upon consultation by the Laboratory, shall confirm, in writing within seven (7) days, whether or not the SSP result shall be confirmed by the Laboratory. The Testing Authority may consult with their APMU, or the Passport Custodian where applicable, in order to reach a decision. If the Testing Authority advises the Laboratory not to proceed with Confirmation Procedures, then it shall provide the reasons for this decision to the Laboratory, which shall update the *ADAMS* test report for the *Sample* accordingly. In the absence of any justification from the Testing Authority, the Laboratory shall proceed with the confirmation analyses (for further details, see TD EAAS).

### C.2.1.7. Departure from *WADA Athlete Biological Passport* requirements

**C.2.1.7.1** If there is a departure from *WADA Athlete Biological Passport* requirements for *Sample* collection, transport and analysis, the biological *Marker* result obtained from this *Sample* affected by the non-conformity shall not be considered in the Adaptive Model calculations (for example, RET% can be affected but not HGB under certain transportation conditions).

**C.2.1.7.2** A *Marker* result which is not affected by the non-conformity can still be considered in the Adaptive Model calculations. In such case, the Athlete Passport Management Unit shall provide the specific explanations supporting the inclusion of the result(s). In all cases, the *Sample* shall remain recorded in the *Athlete's Passport*. The Experts may include all results in their review provided that their conclusions may be validly supported when taking into account the effects of the non-conformity.

## C.2.2 The Initial Expert Review

**C.2.2.1** A Passport generating an *Atypical Passport Finding*, or for which a review is otherwise justified, shall be sent by the Athlete Passport Management Unit to an Expert for review in *ADAMS*. This should take place within seven (7) days following the generation of the *Atypical Passport Finding* in *ADAMS*. The review of the Passport shall be conducted based on the Passport and other basic information (e.g. *Competition* schedules), which may be available, such that the Expert is blinded to the identity of the *Athlete*.

[Comment to Article C.2.2.1: If a result rendered by a Laboratory represents an *Atypical Passport Finding* caused by an atypically high T/E value, the Sample will undergo a Confirmation Procedure, including GC/C/IRMS analysis. If the result of the GC/C/IRMS Confirmation Procedure is negative or inconclusive then the Athlete Passport Management Unit shall seek an Expert review. An Athlete Passport Management Unit or Expert review is not required when the GC/C/IRMS Confirmation Procedure renders an *Adverse Analytical Finding (AAF)*.]

**C.2.2.2** If a Passport has been recently reviewed by an Expert and the Passport Custodian is in the process of executing a specific multi-Sample Testing strategy on the *Athlete*, the Athlete Passport Management Unit may delay the review of a Passport generating an *Atypical Passport Finding* triggered by one of the *Samples* collected in this context until completion of the planned series of tests. In such situations, the Athlete Passport Management Unit shall clearly indicate the reason for delaying the review of the Passport in the Athlete Passport Management Unit report.

**C.2.2.3** If the first and unique result in a Passport is flagged as an *Atypical Passport Finding* by the Adaptive Model, the Athlete Passport Management Unit may recommend the collection of an additional *Sample* before initiating the initial Expert review.

**C.2.2.4** Review in the absence of an *Atypical Passport Finding*

**C.2.2.4.1** A Passport may also be sent for Expert review in the absence of an *Atypical Passport Finding* where the Passport includes other elements otherwise justifying a review.

These elements may include, without limitation:

- a) Data not considered in the Adaptive Model;
- b) Any abnormal levels and/or variations of *Marker(s)*;
- c) Signs of hemodilution in the haematological Passport;
- d) Steroid levels in urine below the corresponding Limit of Quantification of the assay;
- e) Intelligence in relation to the *Athlete* concerned.

**C.2.2.4.2** An Expert review initiated in the above-mentioned situations may result in the same *Consequences* as an Expert review triggered by an *Atypical Passport Finding*.

**C.2.2.5** Expert Evaluation

**C.2.2.5.1** When evaluating a Passport, an Expert weighs the likelihood that the Passport is the result of the *Use of a Prohibited Substance* or *Prohibited Method* against the likelihood that the Passport is the

result of a normal physiological or pathological condition in order to provide one of the following opinions: “Normal”, “Suspicious”, “Likely doping” or “Likely medical condition”. For a “Likely doping” opinion, the Expert shall come to the conclusion that the likelihood that the Passport is the result of the *Use of a Prohibited Substance or Prohibited Method* outweighs the likelihood that the Passport is the result of a normal physiological or pathological condition.

*[Comment to Article C.2.2.5.1: When evaluating competing propositions, the likelihood of each proposition is evaluated by the Expert based on the evidence available for that proposition. It is acknowledged that it is the relative likelihoods (i.e., likelihood ratio) of the competing propositions that ultimately determine the Expert’s opinion. For example, where the Expert is of the view that a Passport is highly likely the result of the Use of a Prohibited Substance or Prohibited Method, it is necessary for a “Likely doping” evaluation that the Expert consider that it is unlikely that it may be the result of a normal physiological or pathological condition. Similarly, where the Expert is of the view that a Passport is likely the result of the Use of a Prohibited Substance or Prohibited Method, it is necessary for a “Likely doping” evaluation that the Expert consider that it is highly unlikely that it may be the result of a normal physiological or pathological condition.]*

**C.2.2.5.2** To reach a conclusion of “Likely doping” in the absence of an *Atypical Passport Finding*, the Expert shall come to the opinion that it is highly likely that the Passport is the result of the *Use of a Prohibited Substance or Prohibited Method* and that it is highly unlikely that the Passport is the result of a normal physiological or pathological condition.

**C.2.3 Consequences of the Initial Review**

Depending on the outcome of the initial review, the Athlete Passport Management Unit will take the following action:

<u>Expert</u> Evaluation	<u>Athlete Passport Management Unit</u> Action
“Normal”	Continue normal <i>Testing</i> plan.
“Suspicious”	Provide recommendations to the <u>Passport Custodian</u> for <i>Target Testing</i> , <i>Sample</i> analysis and/or requesting further information as required.
“Likely doping”	Send to a panel of three (3) <u>Experts</u> , including the initial <u>Expert</u> , as per section C.2 of this Annex C.

“Likely medical condition”	Inform the <i>Athlete</i> as soon as possible via the <u>Passport Custodian</u> (or send to other <u>Experts</u> ).
----------------------------	---

*[Comment to Article C.2.3: The Athlete Biological Passport is a tool to detect the possible Use of Prohibited Substance(s) or Prohibited Method(s) and it is not intended as a health check or for medical monitoring. It is important that the Passport Custodian educate the Athletes to ensure that they undergo regular health monitoring and not rely on the Athlete Biological Passport for this purpose. Nevertheless, the Passport Custodian should inform the Athlete in case the Passport indicates a likely pathology as determined by the Experts.]*

### C.3 Review by Three (3) Experts

**C.3.1** In the event that the opinion of the appointed Expert in the initial review, pending other explanation to be provided at a later stage, is that of “Likely doping”, the Passport shall then be sent by the Athlete Passport Management Unit to two (2) additional Experts for review. This should take place within seven (7) days after the reporting of the initial review. These additional reviews shall be conducted without knowledge of the initial review. These three (3) Experts now constitute the Expert Panel, composed of the Expert appointed in the initial review and these two (2) other Experts.

**C.3.2** The review by the three (3) Experts must follow the same procedure, where applicable, as presented in section C.2.2 of this Annex. The three (3) Experts shall each provide their individual reports in ADAMS. This should take place within seven (7) days after receipt of the request.

**C.3.3** The Athlete Passport Management Unit is responsible for liaising with the Experts and for advising the Passport Custodian of the subsequent Expert assessment. The Experts can request further information, as they deem relevant for their review, notably information related to medical conditions, *Competition* schedule and/or *Sample(s)* analysis results. Such requests are directed via the Athlete Passport Management Unit to the Passport Custodian.

**C.3.4** A unanimous opinion among the three (3) Experts is necessary in order to proceed further towards declaring an *Adverse Passport Finding*, which means that all three (3) Experts render an opinion of “Likely doping”. The conclusion of the Experts must be reached with the three (3) Experts assessing the *Athlete’s Passport* with the same data.

*[Comment to Article C.3.4: The three (3) Expert opinions cannot be accumulated over time based on different data.]*

**C.3.5** To reach a conclusion of “Likely doping” in the absence of an *Atypical Passport Finding*, the Expert Panel shall come to the unanimous opinion that it is highly likely that the Passport is the result of the *Use of a Prohibited Substance or Method* and that there is no reasonably conceivable hypothesis under which the Passport is the result of a normal physiological condition and highly unlikely that it is the result of pathological condition.

**C.3.6** In the case when two (2) Experts evaluate the Passport as “Likely doping” and the third Expert as “Suspicious” asking for more information, the Athlete Passport Management Unit shall confer with the Expert Panel before they finalize their opinion. The group can also seek advice from an appropriate outside Expert, although this must be done while maintaining strict confidentiality of the Athlete’s Personal Information.

**C.3.7** If no unanimity can be reached among the three (3) Experts, the Athlete Passport Management Unit shall report the Passport as “Suspicious”, update the Athlete Passport Management Unit report, and recommend that the Passport Custodian pursue additional Testing and/or gather intelligence on the Athlete (refer to Information Gathering and Intelligence Sharing Guidelines), as appropriate.

#### **C.4 Conference Call, Compilation of the Athlete Biological Passport Documentation Package and Joint Expert Report**

**C.4.1** If a unanimous opinion of “Likely doping” is rendered by all three (3) Experts, the Athlete Passport Management Unit shall declare a “Likely doping” evaluation in the Athlete Passport Management Unit report in ADAMS and should organize a conference call with the Expert Panel to initiate the next steps for the case, including proceeding with the compilation of the Athlete Biological Passport Documentation Package (see *Technical Document* for Athlete Passport Management Units) and drafting of the joint Expert report. In preparation for this conference call, the Athlete Passport Management Unit should coordinate with the Passport Custodian to compile any potentially relevant information to share with the Experts (e.g. suspicious analytical findings, relevant intelligence and relevant pathophysiological information).

**C.4.2** Once completed, the Athlete Biological Passport Documentation Package shall be sent by the Athlete Passport Management Unit to the Expert Panel, who will review it and provide a joint Expert report to be signed by all three (3) Experts. The conclusion within the joint Expert report shall be reached without interference from the Passport Custodian. If necessary, the Expert Panel may request complementary information from the Athlete Passport Management Unit.

**C.4.3** At this stage, the identity of the Athlete is not mentioned but it is accepted that specific information provided may allow to identify the Athlete. This shall not affect the validity of the process.

#### **C.5 Issuing an Adverse Passport Finding**

**C.5.1** If the Expert Panel confirms their unanimous position of “likely doping”, the Athlete Passport Management Unit shall declare an Adverse Passport Finding in ADAMS that includes a written statement of the Adverse Passport Finding, the Athlete Biological Passport Documentation Package and the joint Expert report.

**C.5.2** After reviewing the Athlete Biological Passport Documentation Package and joint Expert report, the Passport Custodian shall:

- a) Notify the Athlete of the Adverse Passport Finding in accordance with Article 5.3.2;

- b) Provide the *Athlete* the *Athlete Biological Passport Documentation Package* and the joint Expert report;
- c) Invite the *Athlete* to provide their own explanation, in a timely manner, of the data provided to the Passport Custodian.

## C.6 Review of Explanation from *Athlete* and Disciplinary Proceedings

**C.6.1** Upon receipt of any explanation and supporting information from the *Athlete*, which should be received within the specified deadline, the *Athlete Passport Management Unit* shall forward it to the Expert Panel for review with any additional information that the Expert Panel considers necessary to render its opinion in coordination with both the Passport Custodian and the *Athlete Passport Management Unit*. At this stage, the review is no longer anonymous. The Expert Panel shall reassess or reassert the case and reach one of the following conclusions:

- a) Unanimous opinion of “Likely doping” by the Experts based on the information in the Passport and any explanation provided by the *Athlete*; or
- b) Based on the available information, the Experts are unable to reach a unanimous opinion of “Likely doping” set forth above.

*[Comment to Article C.6.1: Such a reassessment shall also take place when the Athlete does not provide any explanation.]*

**C.6.2** If the Expert Panel expresses the opinion set forth in section C.6.1(a), then the Passport Custodian shall be informed by the *Athlete Passport Management Unit*, shall charge the *Athlete* in accordance with Article 7 and continue with *Results Management* in accordance with the *International Standard*.

**C.6.3** If the Expert Panel expresses the opinion set forth in section C.6.1(b), the *Athlete Passport Management Unit* shall update the *Athlete Passport Management Unit* report and recommend the Passport Custodian to pursue additional *Testing* and/or gather intelligence on the *Athlete* (refer to Information Gathering and Intelligence Sharing Guidelines), as appropriate. The Passport Custodian shall notify the *Athlete* and WADA of the outcome of the review.

## C.7 Passport Re-setting

**C.7.1** In the event the *Athlete* has been found to have committed an anti-doping rule violation based on the Passport, the *Athlete’s Passport* shall be reset by the Passport Custodian at the start of the relevant period of *Ineligibility* and a new Biological Passport ID shall be assigned in ADAMS. This maintains the *Athlete’s* anonymity for potential *Athlete Passport Management Unit* and Expert Panel reviews conducted in the future.

**C.7.2** When an *Athlete* is found to have committed an anti-doping rule violation on any basis other than the *Athlete Biological Passport*, the haematological and/or Steroidal Passport will remain in effect, except in those cases where the *Prohibited Substance* or *Prohibited Method* caused an alteration of the haematological or steroidal *Markers*, respectively (e.g. for AAF reported for anabolic androgenic steroids, which may affect

the *Markers* of the steroid profile, or for the *Use* of Erythropoiesis Stimulating Agents or blood transfusions, which would alter the haematological *Markers*). The Passport Custodian shall consult with their Athlete Passport Management Unit following an *Adverse Analytical Finding* to determine whether a Passport reset is warranted. In such instances, the *Athlete's* profile(s) would be reset from the time of the beginning of the sanction.

### 3.5 Athlete Passport Management Unit Requirements and Procedures

#### **WADA Technical Document – TD2021APMU**

Document Number:	TD2021APMU	Version Number:	2.0
Written by:	WADA	Approved by:	WADA Executive Committee
Date:	21 November 2020	Effective Date:	01 April 2021

#### 1.0 Introduction

This *Technical Document (TD)* has been established to harmonize effective management of Athlete Passports by providing specific requirements that an Athlete Passport Management Unit (APMU) shall meet in order to be a WADA-approved APMU.

#### 2.0 APMU Roles and Responsibilities

2.1 The APMU is the dedicated unit that is responsible for the timely management of Passports in the *Anti-Doping Administration and Management System (ADAMS)* on behalf of the Passport Custodian. Passport management by the APMU involves:

- a) Performing Passport assessments to make timely *Target Testing* recommendations to the Passport Custodian via the APMU Report in *ADAMS* when appropriate; and
- b) Managing the review of atypical Passports according to Annex C of the *International Standard for Results Management (ISRM)* <sup>[1]</sup>, including, but not limited to, the following:
  - Issuing and updating APMU Reports in *ADAMS*,
  - In case of an *Atypical Passport Finding (ATPF)*, or when a review is otherwise justified, assigning and liaising with the Expert panel as required,
  - Compiling all necessary information to establish an Athlete Biological Passport (ABP) Documentation Package, and
  - Declaring *Adverse Passport Findings (APFs)* to the Passport Custodian and *WADA*.

2.2 The APMU shall assess and manage Passport Sample validity in *ADAMS*, in consultation with the Experts or Laboratories when necessary per Article 8.2 of this *TD*.

2.3 The APMU shall provide support to the Passport Custodian in defining priorities in order to optimize the efficiency of their *ABP* program. These priorities may include, but are not limited to, cost efficiency, special analyses, Test Distribution Plans (TDP), and *Target Testing*.

### 3.0 APMU Hosting

3.1 An APMU shall be hosted by a Laboratory.

*[Comment: Hosting in this context is defined as the provision of facilities and resources for the efficient functioning of the APMU.]*

3.2 APMU hosting by a Laboratory does not preclude the use of qualified APMU managers employed by *ADOs* or other Laboratories.

3.3 Passport management shall be carried out in *ADAMS* using dedicated APMU accounts associated with the host Laboratory regardless of the physical location of the APMU manager(s).

3.4 The host Laboratory shall implement procedures to maintain the operational independence of the APMU, including the appointment of dedicated personnel with a specified time commitment to the APMU and a separate allocation in the budget so that the APMU can continue to function should the *WADA* accreditation of the Laboratory be suspended (see Article **Error! Reference source not found.** of this *TD*).

### 4.0 APMU Personnel

4.1 The host Laboratory shall have a *Person* qualified to function as the designated head of the APMU by assuming professional, organizational, educational, and administrative responsibility of the APMU. The APMU Director is responsible for ensuring the APMU operates in compliance with this *TD* and applicable *International Standards*. In particular, the APMU Director assumes the responsibility of signing and delivering all *APFs* to the Passport Custodian and *WADA*.

*[Comment: The head of the APMU is termed "Director" herein, however use of this title is not a requirement and can be adjusted according to the needs of the organization.]*

4.1.1 The APMU Director's qualifications shall ensure that he or she is competent and capable of leading the APMU operations, including:

- A doctoral degree (or equivalent) in one of the natural sciences or medicine, or in the absence of a doctoral degree, a master's degree (or equivalent) with extensive and appropriate anti-doping science experience and training (*i.e.*, minimum of five (5) years);
- Management experience;
- Ability to oversee compliance with quality management practices; and
- Good command of at least one of *WADA*'s two official languages, English and French.

It is acknowledged that the APMU Director plays an essential role in the APMU operations and that *WADA* APMU approval is delivered based upon appointment of a proper candidate. *WADA* reserves the right to review the credentials of such appointment in accordance with the above qualifications.

4.1.2 The APMU Director is responsible for maintaining documentation for each personnel employed by, or under contract to, the APMU. Such documentation shall contain copies of the curriculum vitae or qualification form, a job description, and records of initial and ongoing training related to anti-doping.

4.1.3 Any personnel changes to the position of APMU Director shall be communicated to WADA no later than one (1) month prior to the date the APMU Director is scheduled to vacate his/her position. A succession plan shall be submitted to WADA.

4.1.4 The APMU Director is notably responsible for monitoring the quality of Passport management and ensuring that other APMU personnel have the experience and training necessary to perform their duties.

4.2 The APMU shall use qualified scientific personnel to serve as APMU manager(s) to manage the Passport review process and Sample validity, and to provide Target Testing and Analytical Testing recommendations through APMU Reports in ADAMS. APMU manager(s) shall be employed by the host Laboratory or be under contract by an ADO or another Laboratory. The APMU should have at least one APMU manager per Module of the ABP.

*[Comment: The designation of “manager” is used herein, however use of this title is not a requirement and can be adjusted according to the needs of the organization. The APMU Director can also serve in the role of APMU manager as required. Where the APMU manager is employed by an ADO, it is assumed that this individual will have access to the identity and other privileged or confidential information about the Athlete, past Testing and/or Results Management and investigations history. This additional information shall not be shared by the APMU manager in the APMU Report but is recognized to be important to contribute to effective Target Testing.]*

4.2.1 APMU manager(s) shall have qualifications in one or more Modules of the ABP. The qualifications are at minimum:

- Bachelor’s degree (or equivalent) in one of the natural or health sciences. Documented experience of three (3) years or more in anti-doping or similar scientific training is equivalent to a Bachelor’s degree for this position; and
- Adequate training in one or more Modules of the ABP, capacity to understand and evaluate analytical results and the physiological response to the Use of Prohibited Substances and Prohibited Methods, as well as criteria relevant for Target Testing.

4.2.2 Where the APMU manager has strong qualifications in Laboratory steroid analysis, steroid doping and metabolism and/or clinical endocrinology, and is not employed by the Passport Custodian, the APMU manager can act as a first Expert for the Steroidal Module of the ABP.

4.3 The APMU should have administrative personnel to coordinate with the Passport Custodian to compile the necessary documentation required for the ABP Documentation Packages, manage communication with various stakeholders and assist with the organization of APMU-related documentation.

## 5.0 APMU Confidentiality and Security

5.1 All APMU related activities shall be carried out in accordance with the confidentiality requirements of the Code and International Standards.

5.2 While APMU activities are typically carried out using Passport data associated with a unique ID, and while APMU staff generally do not have access to data that would enable them to identify Athletes in ADAMS, APMUs may access Personal Information where additional information is

needed to assess a Passport (e.g., when assessing a Passport that has generated an *ATPF*). In such contexts, Personal Information shall only be processed for the purposes set out in this *TD*, and shall be handled by the APMU in accordance with the *International Standard* for the Protection of Privacy and Personal Information (ISPPPI) <sup>[2]</sup> and applicable laws.

5.3 Without limiting the above, the APMU shall adhere to those information retention times set forth in Annex A of the ISPPPI. In consultation with the Passport Custodian, the APMU shall develop specific plans and procedures to ensure the secure retention and eventual destruction of Personal Information.

5.4 The APMU shall develop, maintain, implement and ensure ongoing compliance with a written information security program that includes physical, organizational, technical, environmental and operational safeguards appropriate to the sensitivity of the information in its custody or to which it has access. Such program shall be based on a threat and risk assessment by expert(s) in the relevant field, and shall ensure the confidentiality of its procedures and security of its information systems regardless of the physical location of the APMU personnel at the time of Passport management, such as when the APMU manager is physically located in an *ADO*, another Laboratory or when travelling.

## 6.0 **ABP Expert Panel**

6.1 The APMU shall engage the services of qualified Experts for the review of Passports in accordance with Annex C of the ISRM <sup>[1]</sup>.

6.2 The APMU shall establish, in consultation with the Passport Custodian, a list of Experts who are qualified to comprise an Expert panel for the review of Passports.

- For the Haematological Module, the Expert panel should consist of at least three (3) Experts who have qualifications in one or more of the fields of clinical and laboratory haematology, sports medicine and exercise physiology, as they apply to blood doping;
- For the Steroidal Module, the Expert panel should be composed of at least three (3) individuals with qualifications in the fields of Laboratory steroid analysis, steroid doping and metabolism and/or clinical endocrinology;
- All three (3) Experts forming an Expert panel assigned to review a particular Passport shall not be of one and the same nationality and no two (2) Experts shall have a primary affiliation with the same organization, institution or company, including, but not limited to, universities, hospitals and research institutes.
- At least one Expert on the Expert panel shall currently serve or have previously served as an Expert and reviewed Passports for a WADA-approved APMU.

6.3 The APMU shall ensure that each Expert:

- Has access to relevant *ABP* Expert education resources provided by WADA;
- Has an Expert account created in *ADAMS* by the APMU for the anonymous review of Passports;

- Is independent of the Passport Custodian and has no conflicts of interest in reviewing Passports, as documented in a conflict of interest declaration; and
- Has signed the *WADA ABP Expert* Code of Conduct.

*[Comment: An APMU manager may also concurrently serve as an Expert for other APMUs, provided all requirements of Article 6.0 of this TD are met.]*

## 7.0 Process and Requirements for *WADA APMU* Approval

Passports shall only be managed by APMUs that have been approved by *WADA*.

### 7.1 Applying for *WADA APMU* Approval

#### 7.1.1 Expression of Interest

The candidate APMU shall officially contact *WADA* in writing to express its interest in the *WADA APMU* approval process.

#### 7.1.2 Preliminary Discussion with *WADA*

The purpose of this discussion is to clarify issues with regard to the approval process and to obtain information about different aspects of the APMU relevant to the approval process. Such a discussion could be conducted prior to or during the approval process.

#### 7.1.3 Description of the Candidate APMU

The candidate APMU shall then complete a detailed application form provided by *WADA* and submit it to *WADA* no later than eight (8) weeks following receipt. The application form includes, but is not limited to, the following:

- List of staff, their qualifications and intended role within the APMU;
- Description of the APMU information security program (see Article 5.4 of this *TD*), including a description of the physical, organizational, technical, environmental and operational security measures implemented to protect records and computer systems;
- List of external Experts, their contact information, and their qualifications;
- Business Plan for the APMU and letters of support from *ADOs* that demonstrate a commitment to manage, according to Article 2.0 of this *TD*, a minimum of 100 haematological Passports and 500 steroidal Passports from *Signatories* annually, within one year of receiving approval. An eligible Business Plan shall demonstrate a commitment to provide at least 200 APMU Reports for haematological Passports and 500 APMU Reports for steroidal Passports per year.

#### 7.1.4 Liability Insurance Coverage

The APMU shall provide documentation to *WADA* that professional liability risk insurance coverage or equivalent has been obtained which covers the APMU to an amount of no less than

(≥) 2 million USD annually, and should ensure that the Expert panel has suitable professional liability risk insurance or equivalent coverage.

#### 7.1.5 Operational Independence

The APMU shall ensure a degree of operational independence from the host Laboratory such that the APMU can continue to fulfil its responsibilities in compliance with this *TD* should the *WADA* accreditation of the Laboratory be suspended, where the reason for the Suspension does not have an impact on the function of the APMU. Operational independence implies that the APMU shall have a separate allocation in the budget and sufficient technical and human resources to permit the APMU to manage its own affairs without hindrance or interference by host Laboratories.

#### 7.1.6 Compliance with the *WADA* APMU Code of Ethics

The candidate APMU shall implement and comply with the provisions in the *WADA* APMU Code of Ethics. The APMU shall provide the APMU Code of Ethics to APMU personnel and ensure their understanding and compliance with all aspects. The candidate APMU shall provide to *WADA* a letter of compliance with the APMU Code of Ethics, signed by the APMU director.

#### 7.1.7 *WADA* Recommendation for Approval

After receipt of the application form, *WADA* will complete and submit a report to the candidate APMU. The report will include a recommendation concerning approval of the candidate APMU. In the case where the recommendation is that the APMU should not be approved, the report will identify improvements required in order to be re-considered for designation as a *WADA*-approved APMU. In the case where the recommendation is that the APMU should be approved, the report and recommendation will be submitted to the *WADA* Executive Committee for approval.

#### 7.1.8 Issuing Approval Letter and Publishing APMU List on *WADA*'s Website

A letter signed by a duly authorized representative of *WADA* shall be issued in recognition of approval of an APMU. Such letter shall specify the name of the APMU and the period for which the approval is valid. Approval may be granted with retroactive effect. An updated list of approved APMUs shall be published by *WADA* on *WADA*'s website.

### 7.2 Maintaining *WADA* Approval

An APMU shall continue to function if the Laboratory's accreditation is suspended, provided that the APMU continues to meet other criteria for approval, and that any non-conformities related to the Suspension of the Laboratory's accreditation do not have an impact on the APMU. The APMU's approval shall be revoked if the *WADA* accreditation of the associated Laboratory is revoked.

*[Comment: Suspension or Revocation of APMU approval shall not be considered in decisions on Suspension or Revocation of Laboratory accreditation unless the APMU non-compliance has a clear impact on the function of the Laboratory.]*

#### 7.2.1 Minimum Number of Passports and APMU Reports

In order to maintain proficiency, WADA-approved APMUs are required to review a minimum number of Passports and provide APMU Reports for Passports of Signatory Passport Custodians. WADA shall monitor the total number of Passports under the responsibility of the APMU and the number of APMU Reports issued by the APMU. If the annual number falls below 100 haematological Passports, 500 steroidal Passports, 200 haematological APMU Reports or 500 steroidal APMU Reports, WADA APMU approval may be suspended or revoked.

#### 7.2.2 Documenting Compliance with the WADA APMU Code of Ethics

The APMU shall annually provide to WADA a letter of compliance with the provisions of the APMU Code of Ethics, signed by the APMU Director. All APMU personnel shall sign the WADA APMU Code of Ethics on a yearly basis and the signed documents shall be kept as part of their personnel file. The APMU may be asked to provide documentation demonstrating compliance with the provisions of the APMU Code of Ethics.

#### 7.2.3 Documenting Sharing of Knowledge

The APMU shall proactively share knowledge with other WADA-approved APMUs. The APMU should participate at least once annually in a WADA Working Group or an anti-doping symposium or conference. The APMU shall supply an annual report on sharing of knowledge with WADA. A description of this sharing of knowledge is provided in the WADA APMU Code of Ethics.

#### 7.2.4 Maintaining Professional Liability Insurance Coverage

The APMU shall maintain an ongoing professional liability risk insurance coverage or equivalent which covers the APMU to an amount of no less than ( $\geq$ ) 2 million USD annually, and should ensure that the Expert panel has suitable professional liability risk insurance or equivalent coverage. Proof of the corresponding coverage shall be provided to WADA upon request.

#### 7.2.5 APMU Compliance Monitoring by WADA

WADA shall monitor the compliance of APMUs against the requirements listed in applicable *International Standards* and *TDs*. In addition, WADA shall also conduct at least an annual review of APMU compliance and any other relevant information received or collected by WADA to assess the overall performance of each APMU and to decide its approval status.

#### 7.2.6 APMU Assessment by WADA

WADA reserves the right to conduct document-based audits as well as inspect and assess the APMU through on-site or remote assessments at any time, at WADA's expense. The notice of an on-site assessment will be made in writing to the APMU Director. In exceptional circumstances, the on-site assessment may be unannounced.

#### 7.2.7 Suspension or Revocation of Approval

Suspension or Revocation of APMU approval may occur whenever the APMU fails to comply with applicable *International Standards* and/or *TDs*, or where such measure is otherwise required in order to protect the interests of the anti-doping community.

Without limitation, the following nonconformities in the routine operations of an APMU may be considered in support of Suspension:

- Failure to comply with any of the requirements listed in applicable *International Standards* and/or *TDs*;
- Failure to cooperate with *WADA* or the relevant Testing Authority in providing documentation;
- Noncompliance(s) with the APMU Code of Ethics;
- Major changes in key staff without proper and timely notification to *WADA*;
- Failure to cooperate in any *WADA* inquiry in relation to the activities of the APMU;
- Noncompliance(s) identified from APMU assessment(s); or
- Loss of resources jeopardizing the quality and/or viability of the APMU.

Noncompliance(s) in APMU performance will be assessed by *WADA* on a case-by-case basis considering the severity and consequences to the anti-doping system. Evidence of serious or multiple noncompliance(s) will be reported by *WADA* to an external assessment panel, who will make a recommendation to *WADA* regarding the approval status of the APMU and the required corrective actions and associated deadlines. *WADA* reserves the right to provisionally suspend an APMU's approval pending a full investigation. Such a decision may be taken by the Chair of *WADA*'s Executive Committee.

The period and terms of Suspension shall be proportionate to the seriousness of the noncompliance(s) and the need to ensure reliable management of *Athlete Passports*. A period of Suspension shall be of a duration to be decided by *WADA* and up to a maximum of six (6) months, during which time any nonconformity(ies) must be corrected and such correction documented and reported to *WADA*. If the nonconformity(ies) is/are not corrected during the initial Suspension period, the Suspension shall either be further extended or the APMU approval revoked. The Suspension period may be extended up to a maximum of an additional six (6) months, based on justifiable delays in implementing the satisfactory corrective actions. If the APMU has provided evidence determined to be satisfactory by *WADA* that the noncompliance(s) are corrected, the APMU's approval shall be re-instated. If the APMU has not provided evidence determined to be satisfactory by *WADA* at the end of the extended Suspension period, not to exceed twelve (12) months, the APMU's approval shall be revoked.

During the period of Suspension of the APMU, the management of all *Athlete Passports* shall be transferred by the Passport Custodian to another *WADA*-approved APMU.

The *WADA* Executive Committee shall revoke the approval of any APMU if it determines that Revocation is necessary to ensure reliable management of *Athlete Passports*. Revocation may be based on, but not limited to, the following noncompliances in the routine operations of an APMU:

- Repeated suspensions of *WADA* APMU approval;
- Systematic failure to comply with applicable *International Standards* and/or *TDs*;

- Failure to correct a lack of compliance with any of the requirements listed in applicable *International Standards* and/or *TDs* during a Suspension period;
- A serious or repeated violation of the APMU Code of Ethics;
- Repeated and/or continuous failure to cooperate in any *WADA* inquiry in relation to the activities of the APMU;
- Serious noncompliance(s) identified from APMU assessment(s); or
- Loss of resources jeopardizing the quality and/or viability of the APMU.

#### 7.2.8 Appeals

*WADA*'s decision to suspend or revoke an APMU's approval may be appealed in writing by the APMU before *CAS* within twenty-one (21) days of the date of receipt of notification.

## 8.0 Passport Management and Administration

The APMU shall manage all Passports under the custody of the Passport Custodian.

### 8.1 Passport Review Process

The APMU shall carry out the Passport review process as described in Annex C of the *ISRM* <sup>[1]</sup>.

#### 8.1.1 When assessing a newly matched *Sample* in a Passport:

- The APMU shall assess the validity of individual *Samples* contained within the Passport in *ADAMS* and address any observed irregularities according to Article 8.2 of this *TD* by updating the APMU Report;
- The APMU shall review any new *Samples* within the updated Passport and provide *Target Testing*, *Sample* analysis or other recommendations via the APMU Report as required;
- Where required for its analysis, the APMU may request further information from the Passport Custodian including, but not limited to, circumstances and details of *Sample* collection, transport, and analysis, redacted *Athlete Competition* schedule, travel history, *Athlete* performance, redacted *Athlete* medical information, information on an *Adverse Analytical Finding (AAF)* that is potentially relevant in the context of the Passport, or altitude/whereabouts information which may help them interpret the new *Sample*;
- Where the Passport includes elements justifying a review or upon request by the Passport Custodian, the APMU shall send the Passport to an Expert for review.

*[Comment: One of the benefits of the ABP is the ability to focus resources on atypical results requiring attention. As such, it is not mandatory for an APMU to review all newly matched *Samples* under their responsibility that do not generate a specific notification requiring mandatory follow-up. Nevertheless, at the discretion of the Passport Custodian, an APMU may be requested to review normal Passports.]*

#### 8.1.2 When assessing a Passport that generated an *ATPF*:

- The APMU shall review any previous APMU Reports associated with the Passport;

- The APMU shall assess the validity of individual *Samples* contained within the Passport in *ADAMS*, address any irregularities according to Article 8.2 of this *TD* and update the APMU Report accordingly;
- The APMU shall evaluate the need for urgent *Target Testing* of the *Athlete* and communicate *Testing* recommendations to the Passport Custodian via the APMU Report as required;
- The APMU shall assess the need for additional analysis of existing *Samples* by specific methods (e.g., Agents Affecting Erythropoiesis, Gas Chromatography / Combustion / Isotope Ratio Mass Spectrometry [GC/C/IRMS], etc.) and communicate these to the Passport Custodian via the APMU Report as required. The APMU may also recommend specific *Sample(s)* to be placed in long-term storage.
- If an Expert has previously recommended that follow-up *Testing* include a minimum number of *Samples* before further review of an *Athlete's* Passport data, the APMU may delay sending the Passport for review until the planned number of *Samples* have been analyzed;
- If, after managing the *Sample* validity, the Passport remains atypical, the APMU shall, without delay, send the Passport for review in *ADAMS* by an Expert according to Article C.2.2 of the ISRM <sup>[1]</sup>. In the event of an Expert opinion of:
  - “Likely Doping”: the APMU shall update the APMU Report indicating “Likely Doping”, specifying any detailed analysis or *Testing* recommendations from the Expert (if provided), and continue the Passport review process according to Article C.3 of the ISRM <sup>[1]</sup>;
  - “Suspicious”: the APMU shall update the APMU Report indicating “Suspicious”, highlighting the main atypical features, and outline a *Target Testing* strategy (if necessary) based on the Expert recommendations, or recommend further analysis (e.g., GC/C/IRMS);
  - “Normal”: the APMU shall update the APMU Report indicating “Normal”, summarizing the review by the Expert and outlining any *Testing* recommendations provided by the Expert;
  - “Likely Medical Condition”: the APMU shall update the APMU Report indicating “Likely Medical Condition” with submission to additional Experts if recommended in the Expert evaluation and should inform the *Athlete* via the Passport Custodian. If the first Expert is not a medical doctor, the Passport should be sent to a medical doctor from the Expert panel prior to contacting the Passport Custodian.

#### 8.1.3 When assessing a urine *Sample* that generated an *Atypical Passport Finding - Confirmation Procedure* Request (*ATPF-CPR*; see TD EAAS <sup>[3]</sup>) for the Steroidal Passport:

- The APMU shall assess the validity of the *Sample* generating the Confirmation Procedure (CP) request in *ADAMS*, address any irregularities according to Article 8.2 of this *TD* and update the APMU Report accordingly;

- When the *ATPF-CPR* has been triggered for a *Sample* where the presence of ethanol or other factors impacting the steroid profile have been reported, the APMU shall evaluate the need to perform CP(s) and update the APMU Report accordingly within seven (7) days. Justification not to proceed with CP(s) may include:

- the presence of ethanol glucuronide (EtG) in a *Sample* from an *Athlete* with previous similar findings in his/her Passport with negative GC/C/IRMS results (indicating a pattern of alcohol abuse); or
- communication of the existence of other *AAFs* reported for the *Sample* to the APMU by the Passport Custodian or Testing Authority, as applicable, which would likely lead to a maximum sanction; or
- communication of the existence of a *Therapeutic Use Exemption (TUE)* for the *Athlete* to the APMU by the Passport Custodian or Testing Authority, as applicable.

*[Comment: As stated in the TD EAAS, in such cases, the Passport Custodian, or Testing Authority as applicable, shall advise the Laboratory, in writing and within fifteen (15) days following reception of the *ATPF-CPR* notification, whether or not to proceed with CP(s) of the *Sample's* steroid profile.]*

- In cases when an *ATPF-CPR* is generated for two (2) or more *Samples*, which are linked to a single Sample Collection Session from the same *Athlete*, the APMU should advise the Passport Custodian, and Testing Authority as applicable, to prioritize the confirmation of the *Sample* with the highest concentration of *Markers* of the steroid profile. In such cases, the Passport Custodian, or Testing Authority as applicable, shall advise the Laboratory, in writing and within fifteen (15) days following reception of the *ATPF-CPR* notification, whether or not to proceed with CP(s) of the *Sample's* steroid profile.

#### 8.1.4 When assessing a Suspicious Steroid Profile Confirmation Procedure Request (SSP-CPR):

The APMU will receive an SSP-CPR notification through *ADAMS* when there is no existing steroidal Passport for the *Athlete* in *ADAMS* (*i.e.* this is the first *Sample* in the *Athlete's* steroidal Passport), and the *Sample's* "steroid profile" meets any of the following criteria:

- a) T/E ratio > 4.0;
- b) Concentration of T or E (adjusted for the SG) > 200 ng/mL in males or > 50 ng/mL in females;
- c) Concentration of A or Etio (adjusted for the SG) > 10,000 ng/mL;
- d) Concentration of 5 $\alpha$ Adiol (adjusted for the SG) > 250 ng/mL in males or > 150 ng/mL in females.

Upon receipt of an SSP-CPR notification:

- The APMU shall assess the validity of the *Sample* generating the CP request in *ADAMS*, address any irregularities according to Article 8.2 of this *TD* and update the APMU Report accordingly;

- The APMU shall evaluate the need to perform CP(s) and update the APMU Report accordingly within seven (7) days of receipt of the SSP-CPR notification. The Passport Custodian, or Testing Authority as applicable, shall advise the Laboratory, in writing and within fifteen (15) days following reception of the SSP-CPR notification, whether the Laboratory shall proceed with CP(s)

*[Comment: In the absence of an ATPF-CPR or SSP-CPR, the APMU may also make a recommendation for CPs of the steroid profile, based on assessment by the APMU.]*

#### 8.1.5 Expert Review of Normal Passports

The APMU should provide the Experts from time to time with Passports for review, even when the values are within normal limits and presenting no suspicious elements, as this will ensure that Experts are provided a balanced perspective on the *Athletes' Passports*.

### 8.2 Management of *Sample* Validity

8.2.1 The APMU shall assess and manage the validity of urine and ABP blood *Samples* in ADAMS according to applicable *International Standards* and TDs, including the ISRM <sup>[1]</sup>, TD EAAS<sup>[3]</sup> *International Standard* for Laboratories (ISL) <sup>[4]</sup>, and the *International Standard* for *Testing and Investigations* (ISTI)<sup>[5]</sup>.

8.2.2 Any changes in *Sample* validity made by the APMU shall be noted in applicable fields in ADAMS and in the APMU Report.

8.2.3 Where multiple *Samples* were provided by an *Athlete* during a single Sample Collection Session and are present in a Passport, the APMU shall invalidate all but one *Sample* based on assessment by the APMU.

8.2.4 Where multiple *Samples* were provided by an *Athlete* on the same day from different Sample Collection Sessions and are present in a Passport, the APMU may invalidate all but one *Sample* after assessment by the APMU in consultation with the Passport Custodian, as required

8.2.5 For urine *Samples* where a substance(s) that may alter the steroid profile is detected by the Laboratory (e.g., alcohol), the APMU may invalidate the *Sample* when it is considered to affect the sensitivity of the Adaptive Model to detect changes in future *Samples*.

8.2.6 For ABP blood *Samples* of suspicious profiles where the Blood Stability Score (BSS) could not be calculated, the APMU shall assess the collection-to-analysis time (CAT), any available temperature logger data, and the potential degradation of blood *Markers*, including scattergrams, in order to evaluate *Sample* validity, liaising with (an) Expert(s) as required.

### 8.3 The APMU Report

The APMU Report is a central element in the administrative sequence of the *ABP* that shall be entered and maintained by the APMU in ADAMS. The APMU Report provides an up-to-date overview of the current status of an *Athlete's Passport* together with recommendations, as

appropriate, for efficient follow-up by the Passport Custodian. The APMU Report serves to update the Passport Custodian, WADA and other ADOs with whom the Passport is shared. In addition, it provides a record of events associated with a Passport in ADAMS.

The APMU Report may include, without limitations:

- Assessments of Sample validity by the APMU and/or Experts;
- Recommendations for complementary Analytical Testing (e.g., Agents Affecting Erythropoiesis, HIF stabilizers, confirmation of steroid profile, GC/C/IRMS, long-term steroid Metabolites, IGF-I analogs, etc.) on Samples collected;
- Recommendations for further Analytical Testing on Samples collected previously;
- Recommendations for long-term storage of Samples for Further Analysis;
- Target Testing recommendations based on available data and Experts' recommendations; and
- A summary of any recent Expert reviews.

8.3.1 APMU Reports shall be written in English and should not contain any information that could identify the Athlete.

8.3.2 The APMU Report shall not contain any reference to an AAF that may be known to the APMU, with the exception of when the AAF is used by the APMU as a reason not to perform CP(s) following an ATPF-CPR or SSP-CPR for the steroid profile (see Articles 8.1.3 and 8.1.4 of this TD). If the APMU assessment leads to an Expert review, the APMU may, however, separately inform the Expert(s) of the existence of the AAF. Depending on the result of the Expert review, the APMU shall further inform the Results Management Authority managing the AAF of the result of the Expert review, via the Passport Custodian, if that information is potentially relevant in the context of the Results Management based on the AAF.

*[Comment: While Passport sharing is strongly encouraged to enhance ADO efficiencies and program effectiveness through exchange of information and mutual recognition of program outcomes, this must be carried out within the framework of the ISPPPI [2] and Article 14.1.4 of the Code [6]. The information regarding an AAF shall therefore not be recorded in the APMU Report and shall not be disclosed unnecessarily. Only those individuals and/or organizations involved in the applicable Results Management process should be privy to this information.]*

8.3.3 Target Testing recommendations shall be included in the APMU Report with a sufficient level of detail for the Passport Custodian to conduct effective, timely and appropriate Testing.

#### 8.4 Investigating Urine Exchange

When a urine Sample steroid profile is not consistent with other Sample(s) from the Athlete's Passport, urine exchange with the urine of another individual may be suspected and confirmed using DNA analysis across multiple Samples. This process is managed and reported according to the following steps:

- When evaluating a newly matched urine Sample, where other Samples exist in the Athlete's Passport, the APMU shall evaluate the likelihood that all Samples are from the

same individual. If a *Sample* shows inconsistency compared to others in the Passport (e.g. differences in *Marker* levels), the APMU shall update the APMU Report indicating “Suspicion of Urine Exchange”;

- If the APMU suspects urine exchange, an investigation shall be launched by the Passport Custodian, with support from the APMU, using a combination of actions such as *Sample* storage, confirmation of the steroid profiles of relevant *Samples*, collection of additional *Samples*, and/or DNA analysis, as applicable.

#### 8.4.1 The outcomes of this investigation may indicate:

- a) Confirmation by DNA analysis that all *Samples* belong to the same *Athlete*. In this case, the APMU shall update the APMU Report accordingly.
- b) Multiple DNA profiles are present: where at least two (2) different DNA profiles are identified across different *Samples*, where each urine *Sample* corresponds to a single DNA profile, however the DNA profile corresponding to the *Athlete* under investigation is not known. A strategy shall be undertaken in order to obtain additional *Samples* and the APMU shall update the APMU Report accordingly indicating “Multiple DNA Profiles Identified”.
- c) Confirmed urine exchange: where at least two (2) different DNA profiles have been identified, where each urine *Sample* corresponds to a single DNA profile, and the DNA profile belonging to the *Athlete* is confirmed with a reasonable degree of certainty (e.g. using multiple *Samples*, different *Sample* types, different Sample Collection Personnel). In such cases, the APMU shall update the APMU Report, indicating “Urine Exchange Confirmed”.
- d) Mixed *Samples*: where multiple DNA profiles are found within individual *Samples*. In such cases, the APMU shall liaise with the Passport Custodian, or Testing Authority as applicable, regarding the *Sample* in question to explore whether the Laboratory should consider further investigations towards declaring an AAF for *Sample Tampering* or *Attempted Tampering*.

*[Comment: Where Tampering or Attempted Tampering of a Sample can be established by the analyzing Laboratory based on evidence from that Sample alone (e.g., substitution with another fluid, mixing of urines, addition of proteases to the Sample), the Laboratory can report the finding as an AAF or Atypical Finding for Tampering or Attempted Tampering (see Article 4.0 of the TD EAAS [3]). In contrast, when urine exchange can be established based on steroid profile and/or DNA evidence across multiple Samples, the APMU shall report the finding of confirmed urine exchange to the Passport Custodian, who shall proceed with Results Management according to Code Article 2.2 [6]]*

#### 8.5 Analysis of Steroid Esters

When matched blood *Samples* have been collected during the same Sample Collection Session as urine *Samples* identified with an atypical or suspicious “steroid profile”, the APMU, in consultation with the Passport Custodian, should consider requesting analysis to detect the presence of steroid ester(s) in the associated serum/plasma.

The detection of steroid ester(s) in serum/plasma also constitutes an unequivocal demonstration of the exogenous origin of the steroid(s). On the other hand, the absence of detectable steroid ester(s) in serum/plasma shall not invalidate an *AAF* based on the GC/C/IRMS analysis in urine.

## 8.6 Compiling the ABP Documentation Package

8.6.1 The APMU shall be responsible for compiling the ABP Documentation Package using the template provided by *WADA*. The Passport Custodian shall collect information and bear the cost of compiling ABP Documentation Packages unless it has established an agreement to share the costs with relevant Testing Authorities.

8.6.2 Upon request by the APMU and as needed to compile the ABP Documentation Package, the Passport Custodian shall provide a detailed *Athlete Competition* and altitude schedule, relevant information from *DCFs*, temperature logger and Chain of Custody documentation to the APMU.

8.6.3 The APMU shall confer with the Expert panel to determine the scope of such compilation, including the recommended elements and the number of tests that need to be included. It is only mandatory to have a full blood or urine, as appropriate, *ABP Laboratory Documentation Package* for those tests that are deemed essential by the Expert panel (see TD LDOC <sup>[7]</sup>). Other relevant tests, for example those that confirm the baseline levels of a *Marker*, only require a blood or urine, as appropriate, *ABP Laboratory Certificate of Analysis* (see TD LDOC <sup>[7]</sup>). If the Passport Custodian is not the Testing Authority of the test requiring Laboratory documentation, the Passport Custodian shall coordinate with the Testing Authority to obtain such documentation.

8.6.4 The following key information shall be included for both Haematological and Steroidal Modules of the ABP Documentation Package:

- For the *Athlete*: age (excluding the date of birth), gender, and sport/discipline;
- For all tests: date and time of *Sample* collection, *ADAMS* ordinal number of the test in the Passport, *Sample* code, *Marker* values and graphical results obtained by the Adaptive Model;
- For tests selected by the APMU and Expert panel:
  - *ABP Laboratory Documentation Package(s)* and/or *ABP Certificate(s) of Analysis* from the relevant Laboratory(-ies) and/or ABP Laboratory(-ies) (see TD LDOC <sup>[7]</sup>); and
  - The Passport Custodian shall provide Chain of Custody documentation, *DCF* information and a detailed *Competition* calendar covering the period defined by the selected *Samples*; and
- A compilation of the latest reviews from the Experts or the joint Expert opinion, as applicable.

For the Haematological Module, the following additional information shall be provided for the tests selected by the APMU and Expert panel:

- Temperature profile during the transportation of the blood *Sample* and, when available, the BSS; and
- Responses provided by the *Athlete* on the *ABP* Supplementary Report Form during the *Sample Collection Session*.

For the Steroidal Module, the following additional information shall be provided for the tests selected by the APMU and Expert panel:

- pH of the urine *Sample*;
- Specific gravity (SG) of the urine *Sample*;
- Laboratory documentation, including screening and confirmed (when applicable) values of steroid concentrations and ratios (see TD LDOC <sup>[7]</sup> and TD EAAS <sup>[3]</sup>);
- GC/C/IRMS results, when applicable;
- Indication of ethanol consumption: urinary concentrations of ethanol and/or ethanol *Metabolite(s)*;
- Indication of microbial growth (see TD EAAS <sup>[3]</sup>); and
- Information on the presence or absence of substances that may alter the steroid profile (see TD EAAS <sup>[3]</sup>).

## 9.0 References

[10] The World Anti-Doping Code *International Standard for Results Management*.

[11] The World Anti-Doping Code *International Standard for the Protection of Privacy and Personal Information*.

[12] WADA *Technical Document* TD EAAS: Measurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) *Markers of the Urinary Steroid Profile*.

[13] The World Anti-Doping Code *International Standard for Laboratories*.

[14] The World Anti-Doping Code *International Standard for Testing and Investigations*.

[15] The World Anti-Doping Code.

[16] WADA *Technical Document* TD LDOC: Laboratory Documentation Packages.

[Comment: Current versions of WADA ISL and Technical Documents may be found at <https://www.wada-ama.org/en/what-we-do/science-medical/laboratories> ]

## Part Four: Collaboration Agreement Template

A non-mandatory collaboration agreement template is contained herein to facilitate the exchange of relevant information and mutual recognition of *ABP* program outcomes between *ADOs* that share *Testing* jurisdiction over a single *Athlete* (e.g., *National Anti-Doping Organization* and *International Federation*). *Anti-Doping Organizations* will need to review and modify this template as necessary to ensure it complies with applicable laws.

### Collaboration Agreement

Between

[ • ]

(hereinafter referred to as “[A]” or as a “Party”)

and

[ • ]

(hereinafter referred to as “[B]” or as a “Party”; and collectively with [A], the “Parties”)

**WHEREAS** the principle of the *ABP* is to have a single Passport for each *Athlete*, managed by a single *Anti-Doping Organization (ADO)* referred to as the Passport Custodian;

**WHEREAS** [A] is an [*ADO*] that has *Testing* jurisdiction over certain *Athletes* and wishes to perform Passport Testing in respect of such *Athletes*;

**WHEREAS** [B] is an [*ADO*] that also has *Testing* jurisdiction over those same *Athletes* and also wishes to perform Passport Testing in respect of such *Athletes*;

**WHEREAS** [A] and [B] wish to establish a framework to govern the exchange of *ABP-Related Information* (as defined below) and the mutual recognition of *Athlete Biological Passport (ABP)* program outcomes between [A] and [B] to enhance the efficiency and effectiveness of their respective *ABP* programs.

**THEREFORE**, it is agreed upon between the Parties:

#### Clause 1 - Definitions

Capitalized and italicized terms used in this Agreement shall have the meanings ascribed to them under the World Anti-Doping Code (“*Code*”) while capitalized and underlined terms shall have the meanings ascribed thereto in an *International Standard*, both as amended from time to time. [For ease of reference, relevant definitions have been reproduced in Schedule 1 attached hereto.]

Additional definitions created for the purposes of this Agreement shall be capitalized and have the following meanings:

- 1.1 “*ABP-Related Information*” means any information related to the administration and management of an *ABP* program, including longitudinal profiles of biological Markers; results of the Adaptive Model on Markers data and other information relevant to the evaluation of Markers; APMU and Expert reviews; and *Doping Control* and *Results Management* information related to a relevant Passport.
- 1.2 “*Agreement*” means this Collaboration Agreement, including its preamble.
- 1.3 “*ABP Operating Guidelines*” means the most recent version of the *ABP Operating Guidelines* adopted by *WADA* and available on *WADA*’s website ([www.wada-ama.org](http://www.wada-ama.org)).
- 1.4 “*Representative*” means an employee, officer, Third-Party Agent or other designated adviser or agent of a Party.

## **Clause 2 – Passport Testing and Information Sharing**

- 2.1 Where appropriate and necessary to ensure proper coordination and efficient allocation of Passport Testing activities and resources between the Parties, the Parties agree to provide each other with:
  - (a) a list of *Athletes* (over which [A] and [B] both have *Testing* jurisdiction) within their respective Registered Testing Pool (RTP) or other testing pool (TP) who will be subject to *ABP Testing* in accordance with their test distribution plans (TDP), and to discuss the composition of such TDP with the other Party in advance; and
  - (b) a list of *Events* where each Party intends to conduct pre-*Competition ABP testing*.
- 2.2 For the avoidance of doubt, nothing in this Clause 2 shall prevent [A] or [B] from *Testing* any *Athlete* within its *Testing* jurisdiction for the purposes of its *ABP* at any time, irrespective of the *Athlete*’s status on [A] or [B]’s TDP.
- 2.3 [A] shall conduct *Testing* of the *Athletes* in [A]’s TDP, and [B] shall conduct *Testing* of *Athletes* in [B]’s TDP, including by means of *Target Testing*. For such purposes:
  - (a) Each of [A] and [B] is responsible for ensuring that it has proper *Testing* jurisdiction with regard to any *Testing* activities;
  - (b) Each of [A] and [B] is responsible for ensuring that *Samples* are collected in compliance with the *Code*, the *International Standards*, and the *ABP Operating Guidelines*;
  - (c) Each of [A] and [B] shall each bear its own costs of *Testing* (including the costs of storage, transportation and analysis of *Samples*); and

- (d) The Parties, either directly or through their respective APMUs may share ABP-Related Information with each other as regards the *Target Testing of Athletes* in [A]'s TDP or [B]'s TDP, as the case may be.
- 2.4 Each Party agrees that it shall, at its own cost, exclusively use *ADAMS*, and require its respective APMU to use *ADAMS*, for recording doping control forms and other ABP-Related Information relating to any *Athlete* tested as part of a Party's ABP program.
- 2.5 Where an *Athlete* within a Party's testing pool has been tested as part of a Party's ABP program, the relevant Party shall upload and record all relevant ABP-Related Information on *ADAMS*, or ensure that it is being uploaded and recorded by its APMU, as soon as reasonably practical following the test.
- 2.6 The Party designated as the Passport Custodian, in accordance with clause 3.1 below, agrees that it shall provide the other Party with read-only access to relevant *Athlete Passports* in *ADAMS*. The Parties acknowledge that they may also set specific sharing rules within *ADAMS* to permit each of them automatic access to Passports of Athletes over whom they both have *Testing* jurisdiction.
- 2.7 The Parties acknowledge and agree that where a Party has granted access to a Passport to the other Party within *ADAMS*, such other Party may share ABP-Related Information with its duly authorized Representatives (including its APMU and members of its Expert Panel) strictly for the purposes of its ABP program.
- 2.8 If for whatever reason a Passport or other relevant ABP-Related Information cannot be readily accessed by a Party through *ADAMS*, the Passport Custodian shall provide the relevant Passport or other information to the other Party in such other secure manner as the other Party may reasonably request.

### **Clause 3 – Passport Results Management Process**

- 3.1 For each *Athlete* included in both [A] and [B]'s Registered Testing Pool or other relevant testing pool, the Parties shall agree which Party should act as Passport Custodian to maximise the effectiveness and efficiencies of each Party's respective ABP program, and to ensure the Passport Custodian is the Party that conducts more frequent *Testing* in respect of a given *Athlete*.
- 3.2 The Passport Custodian is responsible for *Results Management* in accordance with the then-current TD on Result Management Requirements for the ABP adopted by WADA. For *Athletes* included in both [A] and [B]'s TDP, Passports shall be reviewed after each test by the APMU of the Passport Custodian independently of whether [A] or [B] was the Testing Authority that conducted the last Passport test.
- 3.3 To the extent this information is not available to the other Party via *ADAMS*, The Parties shall immediately notify each other in writing of the referral of any *Athlete's Passport* for review by the other Party's ABP Expert panel in accordance with the ABP Operating Guidelines, as well as the outcome of such review. The Parties shall also notify each other upon request of an updated list of the members of their ABP Expert panel.

- 3.4 For the avoidance of doubt, relevant *ABP-Related Information* collected by [A] and [B] should, whenever possible, be consolidated for the purposes of pursuing a potential anti-doping rule violation (ADRV) or other *Results Management* procedure against an *Athlete* in accordance with the *Code* and *International Standards*.
- 3.5 Where the Passport Custodian decides not to proceed with an asserted ADRV in connection with a Passport, such decision will not affect the ability of the other Party or WADA to appeal such decision.

#### Clause 4 –Privacy and Security

- 4.1 The Parties acknowledge and agree that the sharing of *ABP-Related Information* (including Personal Information) under this Agreement is necessary to allow each Party to effectively and efficiently manage its *ABP* program and otherwise fulfill its obligations under the *Code* and the *International Standards*.
- 4.2 The Parties agree and acknowledge that each Party is responsible for complying with applicable data protection, privacy and data security laws as well as the *Code* and the *International Standards* with respect to any *ABP-Related Information* exchanged pursuant to this Agreement.
- 4.3 Without limiting the generality of the foregoing, each Party shall:
- (a) ensure that it has a valid legal authority or basis to share *ABP-Related Information* with, or receive such information from, the other Party in connection with this Agreement, as the case may be;
  - (b) treat any *ABP-Related Information* that it receives from the other Party as confidential information at all times and only Process such information for the anti-doping purposes set out in this Agreement and in accordance with the *International Standard* for the Protection of Privacy and Personal Information (ISPPPI);
  - (c) protect any *ABP-Related Information* that it receives from the other Party by applying all necessary and appropriate security safeguards, including physical, organizational, technical, environmental and other measures to prevent against a Security Breach;
  - (d) only grant access and access privileges to any *ABP-Related Information* that it receives from the other Party to its duly authorized Representatives (including its APMU and members of its Expert panel) on a need-to-know basis;
  - (e) subject to clause 4.3(d) above, not disclose any *ABP-Related Information* that it receives from the other Party to any other *Person* without the express prior written consent of the other Party, unless the disclosure is otherwise required by law;
  - (f) ensure any *Person* (including any duly authorized Representative) with access to *ABP-Related Information* is informed of the confidential nature of such information, of the limited purposes for which it can be used, and has entered into a written agreement to preserve such confidentiality; and

- (g) notify the other Party promptly of any Security Breach affecting any *ABP*-Related Information received under this Agreement and take immediate steps to rectify any such Security Breach.

#### **Clause 5 – Effective Date and Termination**

- 5.1 This Agreement shall become effective as of the date of the latest signature appearing on the signature page below and will remain in effect until terminated, except for clause 4 (Privacy and Security) and sub-clause 5.4 of this Agreement which shall survive termination.
- 5.2 Either Party may terminate this Agreement for any reason by providing thirty (30) days' written notice to the other Party.
- 5.3 Either Party may terminate this Agreement immediately if the other Party commits a material breach of any term of this Agreement and (if such breach is remediable) fails to remedy that breach within a period of thirty (30) days after being notified in writing of the breach.
- 5.4 The Parties agree that after the effective date of termination of this Agreement, and subject to applicable data protection and privacy laws, each Party may continue to use all information provided to it by the other Party pursuant to this Agreement, provided that such information is only used for anti-doping purposes in accordance with the *Code* and the *International Standards* and continues to be maintained in accordance with the privacy and security requirements set out in this Agreement, the ISPPPI and applicable laws.

#### **Clause 6 – Authority**

- 6.1 The Parties hereby represent that they have the full power and authority to enter into and perform this Agreement, and the Parties know of no agreement, promises, or undertakings that would prevent the full execution and performance of this Agreement.
- 6.2 Notwithstanding the above and for the avoidance of doubt, the Parties acknowledge and agree that nothing in this Agreement affects or modifies their respective rights and obligations, and those of other relevant third parties, under the "Agreement Governing the Use and Sharing of Information in *ADAMS*" that the Parties entered into with *WADA*.

#### **Clause 7 - Indemnity**

Each Party (the "Breaching Party") shall indemnify and hold harmless the other Party (the "Non-Breaching Party") against any and all costs, charges, damages, expenses and losses (including costs incurred in recovering same) that are incurred by the Non-Breaching Party as a result of any breach of this Agreement by the Breaching Party up to a maximum of [•].

---

**Clause 8 – Miscellaneous**

- 8.1 This Agreement is intended to be the sole and complete statement of obligation of the Parties as to the subject matter hereof, and supersedes all previous agreements, understandings, negotiations and proposals as to such subject matter.
- 8.2 The failure of either Party at any time to demand strict performance of the terms of the Agreement shall not be construed as a waiver of the right to demand or receive complete performance of all rights, promises and covenants in this Agreement.
- 8.3 This Agreement does not establish either Party to be the agent of the other Party or create a joint venture or similar relationship between the Parties and no Party shall have the power to obligate or bind the other Party in any manner whatsoever.
- 8.4 Neither Party may assign, directly or indirectly, by operation of law, change of control or otherwise, this Agreement or any of its rights and obligations hereunder, without the prior written consent of the other Party, which shall not be unreasonably withheld.
- 8.5 The Parties agree that any and all amendments to this Agreement must be made in writing and be signed by both Parties.
- 8.6 If any provision or provisions of this Agreement is be held to be invalid, illegal, or unenforceable, such provision shall be severed from this Agreement to the extent required and the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
- 8.7 A *Person* who is not a party to this Agreement shall not have any rights under or in connection with this Agreement. The rights of the Parties to terminate, rescind or agree any variation, waiver or settlement under this Agreement are not subject to the consent of any *Person* that is not a party to this Agreement.
- 8.8 Section and other headings in this Agreement are for convenience of reference only and shall not constitute a part of or otherwise affect the meaning or interpretation of this Agreement.

**Clause 9 - Notices**

- 9.1 Any notice required to be given under this Agreement shall be in writing and shall be delivered personally, sent by email, fax or sent by commercial courier, to the other Party required to receive the notice at the contact information set out below:
- (a) [A]:  
For the attention of: [•]  
Address: [•]  
Email: [•]  
Fax number: [•]
- (b) [B]:

For the attention of: [•]  
Address: [•]  
Email: [•]  
Fax number: [•]

or at such other address, email or fax as the relevant Party may specify by notice in writing to the other Party.

9.2 Any notice shall be deemed to have been duly given:

- (a) if delivered personally, at the time of delivery at the address referred to in Clause 11.1;
- (b) if delivered by commercial courier, at the time of signature of the courier's receipt;
- (c) if delivered by email, at the date and time indicated on such email; or
- (d) if sent by fax, at the time of transmission.

## **Clause 10 – Applicable Law and Jurisdiction**

10.1 This Agreement and any dispute or claim arising out of or in connection with it or its subject matter shall be governed by and construed in accordance with the law of [•].

10.2 The Parties agree that any dispute, arguments or claims arising with respect to or in connection with the execution of this Agreement (as well as any subsequent amendment hereof, including, for example, its structure, validity, effectiveness, interpretation, execution, infringement or termination, and also any non-contractual claim relating hereto) shall be the object of an amicable resolution. In the absence of amicable resolution, the dispute shall be submitted to the exclusive jurisdiction of the Court of Arbitration for Sport (CAS) in Lausanne, Switzerland, and settled definitively in accordance with the Code of Sports-related Arbitration. The panel will consist of one arbitrator. The language of the arbitration will be [•].

## **Clause 11 - Signatories**

The signatories to this Agreement hereby warrant that they have read and agree to the terms, conditions and provisions of this Agreement, including any Appendices, and have full power and authority to sign for and bind their respective organizations.

## **Clause 12 - Counterparts**

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument.

**In the name and on behalf of**  
**[A]**

.....[Name, Position]

Date: \_\_\_\_\_

**In the name and on behalf of  
[B]**

\_\_\_\_\_

.....[Name, Position]

Date: \_\_\_\_\_